RESEARCH POSTER PRESENTATIONS SESSION III: WEDNESDAY, MAY 25, 2011

Click on the topic below to view posters

POSTER PRESENTATIONS SESSION III
SET-UP: Wednesday, May 25, 2011 - 7:30AM – 8:00AM
POSTER DISPLAY HOURS: Wednesday, May 25, 2011 - 8:00AM – 3:00PM
POSTER AUTHOR DISCUSSION HOUR: Wednesday, May 25, 2011 - 11:45AM - 12:45PM
DISMANTLE: Wednesday, May 25, 2011 - 3:00PM – 3:30PM

Research on Methods – Clinical Outcomes Methods

PRM1

WITHDRAWN

 

 

PRM2

MEASURING DRUG THERAPY GUIDELINES ON OUTCOMES: A TUTORIAL

 

Baser O
STATinMED Research, Ann Arbor, MI, USA

PRM3

THE BURDEN OF CAREGIVING: ASSESSING THE STATUS OF CURRENT CLINICAL RESEARCH

 

Hamer N, Costello S, Roper S, Hamerslag L
Costello Medical Consulting Ltd, Cambridge, UK

Research on Methods – Cost Methods

PRM4

WHAT IS IMPORTANT DURING THE PHARMACOECONOMIC EVALUATION OF CAM (COMPLEMENTARY AND ALTERNATIVE MEDICINE)?—A SURVEY RESEARCH

 

Zhang F1, Li SC2, Fu S1, Xie J1, Zhang Y1, Kong L1
1Shenyang Pharmaceutical University, ShenYang, Liaoning, China, 2University of Newcastle, Callaghan , NSW, Australia

PRM5

A REVIEW AND CLASSIFICATION OF CONTINGENT VALUATION METHOD STUDIES IN SUB-SAHARA AFRICA

 

Kangethe AW, Franic D
University of Georgia, Athens, GA, USA

PRM6

DEVELOPMENT OF AN INCREMENTAL COST-EFFECTIVENESS RATIO WITH SOME EQUITY IMPLICATION

 

Wang JD1, Hung MC2
1National Cheng Kung University College of Medicine, Tainan, Taiwan, 2National Taiwan University, Taipei, Taiwan

PRM7

DRUG DEVELOPMENT AND PHARMACEUTICAL PRICING IN THE UNITED STATES: THE INFLUENCE OF DRUG INTENDED OUTCOMES OF DRUG PRICING

 

Iaconi A, Khalidi N, Olanrewaju O, Balkrishnan R
University of Michigan, Ann Arbor, MI, USA

PRM8

LEGAL RESTRICTIONS ON THE USE OF QALYS IN PHARMACOECONOMIC ANALYSIS IN GERMANY

 

Gissel C, Goetz G, Repp H
Justus Liebig University Giessen, Giessen, Hessen, Germany

PRM9

PHARMACOECONOMICS IN REPUBLIC OF KAZAKHSTAN

 

Kostyuk AV1, Mazhitov TM2, Akanov AB1, Kaptagayeva AK1
1Health Development Institute, Astana, Kazakhstan, 2Astana Medical University, Astana, Kazakhstan

Research on Methods – Databases & Management Methods

PRM10

IS IT FEASIBLE TO COLLECT QUALITY OF LIFE DATA ELECTRONICALLY IN THIN - A UK GENERAL PRACTICE DATABASE?

 

Blak BT, Lee J, Thompson M, Bourke A, Pinder L
Cegedim Strategic Data Medical Research Ltd, London, UK

PRM11

WHY ALGORITHM DOESN'T MATTER IN SYNDROMIC SURVEILLANCE: A COMPARISON OF SYNDROME CLASSIFICATION METHODS

 

Shin J1, Strylewicz G2, Doctor J1
1USC School of Pharmacy, Los Angeles, CA, USA, 2University of Washington, Seattle, WA, USA

Research on Methods – Modeling Methods

PRM12

DOES DIFFERENTIAL DISCOUNTING ENHANCE DECISION MAKING?

 

O'Mahony J, van Rosmalen J
Erasmus University Medical Center, Rotterdam, The Netherlands

PRM13

COMPARISON OF DISCRETE EVENTS SIMULATION SOFTWARE FOR USE IN HEALTH ECONOMICS & OUTCOMES RESEARCH

 

Anaya P
Fundación Mexicana para la Salud AC, Mexico D.F., Mexico

PRM14

VALIDATING AN ONLINE CALCULATOR FOR EVALUATING HEALTH INTERVENTION OPTIONS USING THE ANALYTIC HIERARCHY PROCESS (AHP)

 

McGhan WF, Vichaichanakul K, Willey VJ
University of the Sciences, Philadelphia, PA, USA

Research on Methods – Patient-Reported Outcomes Studies

PRM15

ADHERENCE IS ADHERENCE IS ADHERENCE: THE CONSISTENCY OF MORISKY ADHERENCE SCORES ACROSS THE COSTLIEST CHRONIC CONDITIONS

 

DiBonaventura MD1, Annunziata K2, Goren A1, Gupta S2
1Kantar Health, New York, NY, USA, 2Kantar Health, Princeton, NJ, USA

PRM16

VALIDATION AND PSYCHOMETRIC EVALUATION OF A 5-ITEM MEASURE OF PERCEIVED SOCIAL SUPPORT

 

McCarrier KP1, Bushnell DM1, Martin ML1, Paczkowski R2, Nelson DR2, Buesching D2
1Health Research Associates, Inc., Mountlake Terrace, WA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA

PRM17

DEVELOPMENT AND VALIDATION OF A HEALTH RELATED QUALITY OF LIFE INSTRUMENT TO MEASURE THE IMPACT OF OVER-THE-COUNTER PRODUCT USE AND ASSOCIATED ADVERSE EVENTS

 

Chopra P, Patel H, Sansgiry S
University of Houston, Houston, TX, USA

PRM18

CAN UTILITIES EXCEED 1.0? EMPIRICAL EVIDENCE OF THE CEILING EFFECT

 

Sullivan PW1, Ghushchyan VH2
1Regis University, Rueckert-Hartman College for Health Professions, Denver, CO, USA, 2University of Colorado, Denver, Aurora, CO, USA

PRM19

NON-RESPONSE BIAS IN A SURVEY ASSESSING PATIENTS' MEDICATION AND HEALTH BELIEFS

 

Gadkari A1, McHorney C1, Pedan A2, Gowda N2
1Merck & Co., Inc, North Wales, PA, USA, 2inVentiv Health, Burlington, MA, USA

PRM20

WITHDRAWN

 

 

PRM21

CONVERTING PAPER VERSIONS OF PATIENT REPORTED OUTCOME INSTRUMENTS TO ELECTRONIC VERSIONS: IDENTIFYING THE REQUIRED STEPS

 

Ross J1, O'Gorman HJ2, Peck R1, Ross E1
1Almac Clinical Technologies, Souderton, PA, USA, 2Almac Group, Craigavon, UK

PRM22

STAGES OF NON-PERSISTENCE: A NOVEL WAY OF FRAMING LONGITUDINAL PERSISTENCE TO CHRONIC MEDICATIONS

 

Gadkari A, McHorney C
Merck & Co., Inc, North Wales, PA, USA

PRM23

MEASURING THE IMPACT OF PREVIOUS TREATMENT CYCLES ON HEALTH UTILITY IN PATIENTS RECEIVING BOTULINUM TOXIN TYPE A (BONTA) IN A PROSPECTIVE OBSERVATIONAL COHORT STUDY: MOBILITY STUDY

 

Simonyi S1, Jog M2, Wein T3, Beauchamp R4, Miller R5, Ismail F6, Bhogal M1, Huang B7
1Allergan, Inc., Markham, ON, Canada, 2London Health Sciences Centre, London, ON, Canada, 3McGill University, Montreal, QC, Canada, 4Children's & Women's Health Centre of B.C., Vancouver, ON, Canada, 5Dalhousie University, Halifax, NS, Canada, 6West Park Health Centre, Toronto, ON, Canada, 7McKesson Specialty, Toronto, ON, Canada

PRM24

EXPLORING THE INTERRELATIONSHIP BETWEEN UNINTENTIONAL AND INTENTIONAL NONADHERENCE AMONG 24,071 ADULTS WITH CHRONIC DISEASE

 

Gadkari A, McHorney C
Merck & Co., Inc, North Wales, PA, USA

PRM25

PSYCHOMETRIC COMPARIBILITY OF SINGLE ITEM AND GRID FORM ADMINISTRATION OF THE SF-36V2™ HEALTH SURVEY

 

Smith KJ, Kosinski M
QualityMetric Incorporated, Lincoln, RI, USA

PRM26

IMPACT OF A WEB PORTAL TOOL ON DRIVING PATIENT ADHERENCE

 

Ying X, Khandelwal N, Korcheck R, Duncan I
Walgreens, Deerfield, IL, USA

PRM27

SF-12 AND EQ-5D UTILITY SCORING STRATEGY: LESSONS FROM APPLYING 40 SCORINGS TO 3 LARGE DATA SETS

 

Miller TR1, Bhattacharya S2
1Pacific Institute for Research & Evaluation, Columbia, MD, USA, 2Pacific Institute for Research & Evaluation, Newcastle, WA, USA

PRM28

CREATION OF A NEW PSORIASIS QUALITY OF LIFE MEASURE FROM FIVE PREEXISTENT INSTRUMENTS USING RASCH ANALYSIS: THE CALIPSO QUESTIONNAIRE

 

Sampogna F1, Styles I2, Tabolli S1, Abeni D1
1Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy, 2The University of Western Australia, Perth, Australia

PRM29

METHODOLOGICAL DIFFERENCES IN EQ-5D SCORING SYSTEMS: A SYSTEMATIC REVIEW AND ANALYSIS

 

Perampaladas K, Doble BM, Xie F
McMaster University, Hamilton, ON, Canada

PRM30

RESULTS FROM A NEW VISUAL ANALOGUE SCALE PROTOCOL FOR EQ-5D VALUATIONS

 

Bailey H1, La Foucade A1, Kind P2
1The University of the West Indies, St. Augustine, Trinidad and Tobago, 2University of York, York, UK

PRM31

WITHDRAWN

 

 

PRM32

VALIDITY EVIDENCE AND VALIDATION PRACTICE IN PAPERS PUBLISHED IN VALUE IN HEALTH (1998-2010): A SYSTEMATIC REVIEW

 

Chan EKH1, Darmawanti I2, Mulyana OP2, Zumbo BD1
1University of British Columbia, Vancouver, BC, Canada, 2State University of Surabaya, Surabaya, East Java, Indonesia

PRM33

TAKE TIME TO TRAIN: EVIDENCE TO SHOW THAT PATIENT TRAINING IN ELECTRONIC PATIENT REPORTED OUTCOMES IS BENEFICIAL

 

Ross J1, Ross E1, O'Gorman HJ2, Peck R1
1Almac Clinical Technologies, Souderton, PA, USA, 2Almac Group, Craigavon, UK

PRM34

EVALUATING THE SCREENING ABILITY OF PATIENT-REPORTED OUTCOME INSTRUMENTS

 

Coon C1, McLeod L1, Arnold L2, Chandran A3, Martin S4
1RTI Health Solutions, Research Triangle Park, NC, USA, 2University of Cincinnati College of Medicine, Cincinnati, OH, USA, 3Pfizer, Inc., New York, NY, USA, 4RTI Health Solutions, Ann Arbor, MI, USA

PRM35

DEVELOPMENT OF A CONCEPT LIST TO ENSURE COMPARABLE CONTENT VALIDITY BETWEEN ORIGINAL PRO QUESTIONNAIRES AND THEIR TRANSLATIONS: A REVIEW OF 15 YEARS OF LINGUISTIC VALIDATIONS

 

Mear I1, Conway K2
1MAPI Institute, Lyon, France, 2MAPI Research Trust, Lyon, France

Research on Methods – Statistical Methods

PRM36

NONPARAMETRIC ESTIMATION OF INCREMENTAL COST EFFECTIVENESS RATIO ACCOUNTING FOR SKEWNESS

 

Blough DK
University of Washington, Seattle, WA, USA

PRM37

THE DISCRETE MODELLING OF INTERVENTIONS WITH CONTINUOUSLY VARYING COSTS AND EFFECTS: IMPLICATIONS FOR ICERS, CEACS AND EVPI

 

O'Mahony J, van Rosmalen J
Erasmus University Medical Center, Rotterdam, The Netherlands

PRM38

THE EXTENSION OF THE COST-EFFECTIVENESS ACCEPTABILITY CURVE: HOW TO MAKE IT MORE INFORMATIVE?

 

Kamae I1, Araki D2, Kamae M3
1Keio University Graduate School of Health Management, Fujisawa, Japan, 2Meiji University of Integrative Medicine School of Nursing Science, Nantan-shi, Kyoto, Japan, 3Tufts Medical Center, Boston, MA, USA

Research on Methods – Study Design

PRM39

LITERATURE REVIEW OF RANDOMIZED, CONTROLLED STUDIES OF THE IMPACT OF PHARMACISTS' INTERVENTIONS TO IMPROVE PATIENT OUTCOMES

 

Kharat AA1, Borrego M1, Raisch DW2
1University of New Mexico, Albuquerque, NM, USA, 2University of New Mexico College of Pharmacy, Albuquerque, NM, USA

Research on Methods – Conceptual Papers

PRM40

ISSUES CONCERNING THE TRANSLATION OF THE WORD ‘HASSLED' IN THE MORISKY MEDICATION ADHERENCE SCALE (MMAS-8)

 

Griffin A1, Wild D1, Morisky DE2
1Oxford Outcomes Ltd., Oxford, Oxfordshire, UK, 2UCLA School of Public Health, Los Angeles, CA, USA

PRM41

IS IT TIME TO ELIMINATE THE ICER? USING NET BENEFITS TO REPORT THE RESULTS OF DETERMINISTIC COST-EFFECTIVENESS ANALYSES

 

O'Day K, McLaughlin T, Bramley T
Xcenda, LLC., Palm Harbor, FL, USA

PRM42

VISUALLY EVALUATING THE MEASUREMENT COMPARABILITY BETWEEN PAPER-BASED AND ALTERNATE VERSIONS OF ADMINISTRATION OF THE LUNG FUNCTION QUESTIONNAIRE

 

Gilligan T1, Nelson L1, McLeod L1, Dalal AA2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline, Durham, NC, USA

PRM43

BIOSIMILARS: DEMONSTRATING SIMILARITY THROUGH EVIDENCE

 

Kleintjens J1, Dahal D1, Mai JC1, Doyle JJ2
1Quintiles, Hawthorne, NY, USA, 2Columbia University, New York, NY, USA

PRM44

OPTIMUM METHODS FOR PRO TRANSLATION AND LINGUISTIC VALIDATION METHODOLOGY: ONE BACK TRANSLATION OR TWO?

 

Furtado T, Anderson H, Griffin A, Wild D
Oxford Outcomes Ltd., Oxford , UK

PRM45

PILOT TESTING TRANSLATIONS OF PRO MEASURES WITH SENSITIVE POPULATIONS

 

Verjee-Lorenz A, Clayson D, Two R
PharmaQuest Ltd, Banbury, Oxfordshire, UK

PRM46

R… YOU AWARE HOW USEFUL IT IS? THE VALUE OF CORRELATION COEFFICIENTS IN META-ANALYSIS

 

Al-Dakkak I, Patel S, Jen MH, von Maltzahn R
HERON Evidence Development Ltd, Luton, UK

PRM47

DEVELOPMENT OF LOCALLY ADAPTABLE VALUE ARGUMENTS: HOW CAN BUCKETING OF COUNTRIES AT GLOBAL LEVEL HELP MANUFACTURERS?

 

Kirpekar S, Dummett H
Double Helix Consulting, London, UK

PRM48

DESIGN AND OPERATIONAL CONSIDERATIONS FOR PRAGMATIC CLINICAL TRIALS TO SUPPORT HEOR EVALUATIONS

 

Ishak KJ1, Payne KA1, Schrammel M2, Caro JJ3
1United BioSource Corporation, Dorval, QC, Canada, 2United BioSource Corporation, Boulder, CO, USA, 3United BioSource Corporation, Lexington, MA, USA

PRM49

TRANSLATION AND LINGUISTIC VALIDATION – METHODOLOGICAL IMPLICATIONS WHEN THE SOURCE MEASURE IS NOT ENGLISH

 

Clayson D1, Verjee-Lorenz A1, Two R1, Gerber R2, Beaudreuil J3
1PharmaQuest Ltd, Banbury, Oxfordshire, UK, 2Pfizer, Inc., New London, CT, USA, 3Université Paris, Paris, France

POSTER PRESENTATIONS SESSION III
SET-UP: Wednesday, May 25, 2011 - 7:30AM – 8:00AM
POSTER DISPLAY HOURS: Wednesday, May 25, 2011 - 8:00AM – 3:00PM
POSTER AUTHOR DISCUSSION HOUR: Wednesday, May 25, 2011 - 11:45AM - 12:45PM
DISMANTLE: Wednesday, May 25, 2011 - 3:00PM – 3:30PM

Cancer – Clinical Outcomes Studies

PCN1

CHEMOTHERAPY INDUCED NAUSEA AND VOMITING EVENT RATE AMONG PATIENTS WITH CANCER TREATED WITH HIGHLY OR MODERATELY EMETOGENIC CHEMOTHERAPY AND INITIATED ON PALONOSETRON VERSUS OTHER 5-HT3-RECEPTOR ANTAGONIST ANTI-EMETIC PROPHYLAXIS IN A HOSPITAL OUTPATIENT SETTING

 

Craver C1, Gayle J1, Balu S2, Buchner D2
1Premier, Inc., Charlotte, NC, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA

PCN2

SAFETY AND TREATMENT PATTERNS OF ANGIOGENESIS INHIBITORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN THE UNITED KINGDOM: PRELIMINARY RESULTS OF AN ONGOING CHARTS REVIEW STUDY

 

Hawkins R1, Wagstaff J2, Nathan P3, Sarda SP4, Vekeman F5, Korves C4, Dasgupta S2, O'Mara S1, Fitton S1, Hayers J1, Tham C1, Wei R4, Luka A4, Neary MP6, Duh MS4
1University of Manchester, Manchester, UK, 2Singleton Hospital, Swansea, UK, 3Mount Vernon Cancer Center, Northwood, Middlesex, UK, 4Analysis Group, Inc., Boston, MA, USA, 5Analysis Group, Inc., Washington, DC, USA, 6GlaxoSmithKline, Collegeville, PA, USA

PCN3

CARDIOVASCULAR COMORBIDITIES AMONG PATIENTS WITH METASTATIC COLORECTAL CANCER

 

Overbeek JA1, Zhao Z2, van Herk-Sukel MPP1, Barber BL2, Gao S2, Herings RMC1
1PHARMO Institute, Utrecht, The Netherlands, 2Amgen, Inc., Thousand Oaks, CA, USA

PCN4

BODY MASS INDEX AND STAGE OF DIAGNOSIS OF OVARIAN CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS

 

Blieden MB
Harvard University, Boston, MA, USA

PCN5

USING HEALTH CLAIMS DATA TO STUDY PATTERNS OF CERVICAL CANCER SCREENING AND DIAGNOSIS IN A STATE MEDICAID FEE-FOR-SERVICE POPULATION (FUNDING: AHRQ – P20-HS15930)

 

Nadpara P1, Madhavan S1, Khanna R2, Atkins E1, Smith MJ3, Miller LA1
1West Virginia University, Morgantown, WV, USA, 2University of Mississippi, University, MS, USA, 3University of Oklahoma, Tulsa, OK, USA

PCN6

BREAST, PROSTATE AND COLORECTAL CANCER SCREENING BEHAVIOR AND INCIDENCE OF LATE STAGE CANCER DIAGNOSIS IN ELDERLY WEST VIRGINIANS

 

Nadpara P1, Madhavan S1, Tworek C2
1West Virginia University, Morgantown, WV, USA, 2West Virginia University School of Pharmacy, Morgantown, WV, USA

PCN7

COMPARATIVE EFFECTIVENESS ASSESSMENT OF ERLOTINIB VERSUS GEFITINIB IN FIRST-LINE EGFR ACTIVATING MUTATION POSITIVE NON-SMALL CELL LUNG CANCER

 

Schwander B1, de Castro Carpeño J2, Heigener DF3, Wright E4, Bischoff HG5, Walzer S4
1AiM GmbH - Assessment in Medicine, Research and Consulting, Lörrach, Germany, 2University Hospital of de La Paz, Madrid, Spain, 3Hospital Grosshansdorf, Grosshansdorf, Germany, 4F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland, 5Thoracic Hospital of Heidelberg GmbH, Heidelberg, Germany

PCN8

REAL LIFE OUTCOMES IN 1ST LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A PILOT STUDY IN FRANCE AND GERMANY ANALYSING BEVACIZUMAB-BASED VERSUS NON-BEVACIZUMAB-BASED TREATMENTS

 

Bischoff HG1, Chouaid C2, Vergnenegre A3, Heigener DF4, Taylor-Stokes G5, Roughley A5, Walzer S6
1Thoraxklinik Heidelberg GmbH, Hedelberg, Germany, 2Hôpital Saint Antoine, Paris, France, 3SIME, Limoges, France, 4Krankenhaus Grosshansdorf, Grosshansdorf, Germany, 5Adelphi Real World, Macclesfield, Cheshire, UK, 6F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland

PCN9

VALUE OF RESEARCH ANALYSES IN RESEARCH PRIORITIZATION OF CANCER GENOMIC APPLICATIONS

 

Carlson J1, Thariani R1, Roth J2, Ramsey S3, Deverka P4, Esmail L4, Gralow J1, Henry NL5, Veenstra D2
1University of Washington, Seattle, WA, USA, 2University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA, 3Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA, 4Center for Medical Technology and Policy, Baltimore, MD, USA, 5University of Michigan Medical School, Ann Arbor, MI, USA

PCN10

ARE FURTHER STUDIES OF BREAST CANCER TUMOR MARKERS TO DETECT RECURRENCE WORTHWHILE? A VALUE OF RESEARCH ANALYSIS

 

Thariani R1, Carlson JJ1, Steuten L2, Gralow J3, Henry NL4, Ramsey S5, Veenstra D6
1University of Washington, Seattle, WA, USA, 2University of Twente, Enschede , The Netherlands, 3Seattle Cancer Care Alliance, Seattle, WA, USA, 4University of Michigan Medical School, Ann Arbor, MI, USA, 5Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA, 6University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA

PCN11

COMPARATIVE EFFECTIVENESS RESEARCH: ERECTILE DYSFUNCTION LONGITUDINAL COSTS ACROSS TREATMENTS FOR PROSTATE CANCER

 

Wilson LS, Basu R, Paoli C, Lian V, Wong A, Kuo J, Sadetsky N, Cooperberg M, Carroll P
University of California, San Francisco, San Francisco, CA, USA

PCN12

RESOURCE UTILIZATION AND PERCEPTIONS OF MAJOR MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML): RESULTS OF A DELPHI PANEL STUDY

 

Bollu V1, Quintas-Cardama A2, Flamm M3, Lill M4, Thirman M5, Ravandi-Kashani F2, Akard L6, Talpaz M7
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 3Columbia University Medical Center, New York, NY, USA, 4Cedars-Sinai Medical Center, Los Angeles, CA, USA, 5University of Chicago, Chicago, IL, USA, 6Indiana Blood and Marrow Transplantation, Beech Grove, IN, USA, 7University of Michigan Health Systems, Ann Arbor, MI, USA

PCN13

REAL LIFE OUTCOMES IN 2ND LINE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A PILOT STUDY IN FRANCE AND GERMANY ANALYSING ERLOTINIB VERSUS CHEMOTHERAPY

 

Vergnenegre A1, Heigener DF2, Bischoff HG3, Chouaid C4, Taylor-Stokes G5, Roughley A5, Walzer S6
1SIME, Limoges, France, 2Krankenhaus Grosshansdorf, Grosshansdorf, Germany, 3Thoraxklinik Heidelberg GmbH, Hedelberg, Germany, 4Hôpital Saint Antoine, Paris, France, 5Adelphi Real World, Macclesfield, Cheshire, UK, 6F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland

PCN14

UNMET NEED IN METASTATIC PROSTATE CANCER PATIENTS: RESULTS FROM A SYSTEMATIC REVIEW

 

Wu Y1, Modha R2, Sehgal M3, Dhawan R4
1Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, USA, 2Heron Health, Stopsley, Luton, UK, 3Heron Health, Chandigarh, India, 4Johnson & Johnson Pharmaceutical Services, LLC, Raritan, NJ, USA

PCN15

CORRELATES FOR HUMAN PAPILLOMA VIRUS VACCINATION UPTAKE IN A LARGE HEALTH ORGANIZATION IN ISRAEL

 

Chodick G, Shalev V, Raz R, Schejter E
Maccabi Healthcare Services, Tel Aviv, Israel

PCN16

MAJOR CHANGES IN CHEMOTHERAPY REGIMENS ADMINISTERED TO BREAST CANCER PATIENTS DURING 2000-2008

 

van Herk-Sukel MPP1, van de Poll L2, Creemers GJ3, Lemmens V4, van der Linden P5, Herings RMC1, Coebergh JW6, Voogd A7
1PHARMO Institute, Utrecht, The Netherlands, 2Comprehensive Cancer Center South, Eindhoven, Noord-Brabant, The Netherlands, 3Catharina Ziekenhuis, Eindhoven, Noord-Brabant, The Netherlands, 4Comprehensive Cancer Center, Eindhoven, Noord-Brabant, The Netherlands, 5Tergooi Ziekenhuizen, Blaricum, Utrecht, The Netherlands, 6Erasmus University Medical Center, Rotterdam, Zuid-Holland, The Netherlands, 7Universiteit Maastricht, Maastricht, Limburg, The Netherlands

PCN17

WITHDRAWN

 

 

PCN18

AN EPIDEMIOLOGICAL MODEL OF PROSTATE CANCER AND PROGRESSION TO BONE METASTASES IN THE UNITED KINGDOM

 

Cure S1, Martin M1, Bracco A2, Brown J3, Kearney M2
1i3 Innovus, Uxbridge, Middlesex, UK, 2Amgen (Europe) GmbH, Zug, Switzerland, 3St. James's University Hospital, Leeds, UK

PCN19

AN EPIDEMIOLOGICAL MODEL OF BREAST CANCER AND PROGRESSION TO BONE METASTASES IN THE UNITED KINGDOM

 

Martin M1, Kearney M2, Bracco A2, Brown J3
1i3 Innovus, Uxbridge, Middlesex, UK, 2Amgen (Europe) GmbH, Zug, Switzerland, 3St. James's University Hospital, Leeds, UK

PCN20

EXERCISE LOWERS ESTROGEN AND PROGESTERONE LEVELS IN PREMENOPAUSAL WOMEN AT HIGH RISK OF BREAST CANCER

 

Kossman D1, Williams N2, Domchek S3, Kurzer M4, Stopfer J3, Schmitz K3
1National Analysts Worldwide, Philadelphia, PA, USA, 2Pennsylvania State University, University Park, PA, USA, 3University of Pennsylvania, Philadelphia, PA, USA, 4University of Minnesota, St. Paul, MN, USA

PCN21

PATTERNS OF ANGIOGENESIS INHIBITOR TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN IRELAND

 

McDermott R1, Donnellan P2, McCaffery J3, Keane F2, Sarda SP4, Korves C4, Luka A4, Wei R4, Neary MP5, Hanley R6, Duh MS4
1Adelaide & Meath Hospital, Dublin, Ireland, 2University College Hospital Galway, Galway, Ireland, 3Mater Misericordiae University Hospital, Dublin, Ireland, 4Analysis Group, Inc., Boston, MA, USA, 5GlaxoSmithKline, Collegeville, PA, USA, 6GlaxoSmithKline, Dublin, Ireland

PCN22

ASSESSMENT OF SAFETY PROFILE OF TRASTUZUMAB IN METASTATIC BREAST CANCER PATIENTS

 

Rana C, Mann K, Wadhwa A
Heron Health Private Ltd, Chandigarh, Chandigarh, India

PCN23

IMPACT OF UNITED STATES FOOD AND DRUG ADMINISTRATION'S BLACK BOX WARNINGS ON ADVERSE EVENTS REPORTING RATES FOR MULTIPLE MYELOMA DRUGS

 

Garg V1, Raisch DW1, Mckoy J2, Trifilio S3, Holbrook J2, Samaras AT2, West D2
1University of New Mexico, Albuquerque, NM, USA, 2Northwestern University, Chicago, IL, USA, 3Northwestern Memorial Hospital, Chicago, IL, USA

PCN24

FACTORS ASSOCIATED WITH LATE-STAGE PROSTATE CANCER SURVIVAL IN FLORIDA

 

Adunlin GB, Xiao H
Florida A&M University, Tallahassee, FL, USA

Cancer – Cost Studies

PCN25

BUDGET-IMPACT OF ERIBULIN FOR THIRD-LINE TREATMENT OF METASTATIC BREAST CANCER IN A UNITED STATES MANAGED CARE SETTING

 

Tao C1, Taylor D1, Parthan A2, Faria C3, Choe Y3
1i3 Innovus, Medford, MA, USA, 2i3 Innovus, San Francisco, CA, USA, 3Eisai, Inc., Woodcliff Lake, NJ, USA

PCN26

BUDGET IMPACT MODEL OF DENOSUMAB FOR SKELETAL RELATED EVENT (SRE) PREVENTION IN PATIENTS WITH BREAST AND PROSTATE CANCER

 

Northridge K1, Richhariya A2, Halperin M1, Chung K2, Danese MD1
1Outcomes Insights, Inc., Westlake Village, CA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA

PCN27

COMPARATIVE BUDGET IMPACT OF FORMULARY INCLUSION OF ZOLEDRONIC ACID AND DENOSUMAB FOR PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES

 

Bell MJ1, Miller JD2, Namjoshi M3, Russell MW2
1RTI Health Solutions, Manchester, UK, 2RTI Health Solutions, Waltham, MA, USA, 3Novartis Oncology US, East Hanover, NJ, USA

PCN28

COST SAVINGS WITH FERRIC CARBOXYMALTOSE THROUGH ITS IMPACT ON ERYTHROPOÏESIS-STIMULATING AGENTS AND BLOOD TRANSFUSION IN CHEMOTHERAPY-INDUCED ANEMIA OF BREAST AND GASTROINTESTINAL CANCER: FRENCH HEALTH CARE PAYER PERSPECTIVE

 

Luporsi E1, Mahi L2, Moore C3, Wernli J4, Bugat R5
1Centre Alexis Vautrin, Vandoeuvre-Les-Nancy, France, 2Vifor Pharma AG, Neuilly sur Seine, France, 3JNBD-Développement, Paris, France, 4Vifor Pharma AG, Glattbrugg, Switzerland, 5Institut Claudius Regaud, Toulouse, France

PCN29

TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) USING RITUXIMAB (R) WITH FLUDARABINE (F) AND CYCLOPHOSPHAMIDE (C): ASSESSING THE FINANCIAL IMPACT OF THE ROUTE OF ADMINISTRATION AT PRINCESS MARGARET HOSPITAL (PMH)

 

Douglas P1, Lee R2, Worthington K1, Mistry B1
1Hoffmann-La Roche Limited, Mississauga, ON, Canada, 2University Health Network, Toronto, ON, Canada

PCN30

DOES A LACK OF HTA REVIEW LEAD TO HIGHER PRICES FOR HIV TREATMENTS? A COMPARISON WITH ONCOLOGY TREATMENTS

 

Nordyke R1, Imbeah-Ampiah R2, Ng-Haing J2, Oshinowo B2, Saraf S2
1PriceSpective LLC, El Segundo, CA, USA, 2PriceSpective Ltd., London, UK

PCN31

DIRECT MEDICAL COSTS OF ELDERLY PATIENTS WITH STAGE III COLON CANCER DURING FIRST-LINE VERSUS SECOND-LINE CHEMOTHERAPY

 

Yang HK, Bikov K, Onukwugha E, Mullins CD
University of Maryland School of Pharmacy, Baltimore, MD, USA

PCN32

COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN CHRONIC KIDNEY DISEASE AND CHEMOTHERAPY-INDUCED ANEMIA OUTPATIENTS

 

Lafeuille MH1, Bailey RA2, Senbetta M2, McKenzie RS2, Lefebvre P1
1Groupe d'analyse, Ltée, Montreal, QC, Canada, 2Centocor Ortho Biotech Services, LLC, Horsham, PA, USA

PCN33

COST SAVINGS ASSOCIATED WITH TRANSFUSION INDEPENDENCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME WITH A 5Q- DELETION

 

Bozkaya D1, Mahmoud D2, Mitsi G3, Khan ZM2
1United BioSource Corporation, Lexington, MA, USA, 2Celgene, Summit, NJ, USA, 3United BioSource Corporation, Santa Ana, CA, USA

PCN34

LONG-TERM DIRECT MEDICAL COSTS IN PATIENTS DIAGNOSED WITH FOLLICULAR LYMPHOMA WHO RECEIVE FRONTLINE CHEMOTHERAPY WITH VERSUS WITHOUT RITUXIMAB - A SEER MEDICARE ANALYSIS

 

Griffiths RI1, Gleeson ML1, Mikhael JR2, Danese MD1
1Outcomes Insights, Inc., Westlake Village, CA, USA, 2Mayo College of Medicine, Scottsdale, AZ, USA

PCN35

DOSING PATTERN AND COST COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA IN CHRONIC KIDNEY DISEASE AND CHEMOTHERAPY-INDUCED ANEMIA INPATIENTS

 

Lafeuille MH1, Bailey RA2, Senbetta M2, McKenzie RS2, Lefebvre P1
1Groupe d'analyse, Ltée, Montreal, QC, Canada, 2Centocor Ortho Biotech Services, LLC, Horsham, PA, USA

PCN36

COST ANALYSIS, SAFETY, AND EFFICACY OF PEMETREXED/CISPLATIN COMPARED WITH BEVACIZUMAB/GEMCITABINE/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NSCLC IN RUSSIA

 

Davey P1, Rajan N2, Kanivets Y3, Barraclough H2, Orlando M4, Brnabic AJ5, Han B6
1Illuminate Health Consulting, Sydney, NSW, Australia, 2Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia, 3Eli Lilly Vostok S.A., Moscow, Russia, 4Eli Lilly Interamerica Inc, Buenos Aires, Argentina, 5Eli Lilly Australia Pty Ltd, Sydney, NSW, Australia, 6Eli Lilly and Company, Indianapolis, IN, USA

PCN37

ESTIMATING COST OF TREATMENT IN ELDERLY PATIENTS WITH COLORECTAL CANCER USING MEDICARE DATA

 

Kokkotos F, Shen S, Wang Z, Zhang Y
Trinity Partners, LLC, Waltham, MA, USA

PCN38

FIRST-YEAR COSTS FOR THE 19 MOST COMMON CANCER DIAGNOSES IN ONTARIO

 

de Oliveira C1, Bremner K1, Chan K2, Gunraj N3, Krahn M4
1University Health Network, Toronto, ON, Canada, 2Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 3Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 4Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada

PCN39

COSTS AT THE END OF LIFE FOR PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

 

Alemayehu B1, Parry D2, Engel-Nitz NM3, Kulakodlu M3, Nathan F1
1AstraZeneca, Wilmington, DE, USA, 2AstraZeneca, Macclesfield, Cheshire, UK, 3i3 Innovus, Eden Prairie, MN, USA

PCN40

HEALTH CARE UTILIZATION AND COSTS OF RESECTED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN AN INCIDENT COHORT OF PATIENTS IN THE UK

 

Kim K1, Amonkar M2, Högberg D1, Kasteng F1
1i3 Innovus, Stockholm, Sweden, 2GlaxoSmithKline, Collegeville, PA, USA

PCN41

FINANCIAL BURDEN AMONG PATIENTS WITH MAJOR CANCERS: FINDINGS FROM THE UNITED STATES MEDICAL EXPENDITURE PANEL SURVEY, 1996-2007

 

Lang K, Huang H, Rodriguez L, Menzin J
Boston Health Economics, Inc., Waltham, MA, USA

PCN42

COSTS OF HOSPITAL EVENTS IN PATIENTS WITH METASTATIC COLORECTAL CANCER

 

Overbeek JA1, Zhao Z2, van Herk-Sukel MPP1, Barber BL2, Gao S2, Herings RMC1
1PHARMO Institute, Utrecht, The Netherlands, 2Amgen, Inc., Thousand Oaks, CA, USA

PCN43

STUDY ON MEDICAL EXPENDITURE AND PAYMENT PATTERNS OF INSURED PATIENTS WITH CANCER IN CHINA

 

Xiong X1, Lin J1, Chen W2
1China Health Insurance Research Association, Beijing, China, 2Fudan University, Shanghai, China

PCN44

WITHDRAWN

 

 

PCN45

WITHDRAWN

 

 

PCN46

HEALTH CARE EXPENDITURES, DISABILITY DAYS, AND RESOURCE UTILIZATION ASSOCIATED WITH CANCER IN UNITED STATES EMPLOYER SETTINGS

 

Tang D1, Alberts DS1, Nevins R2, Sullivan S2, Skrepnek GH1
1The University of Arizona, Tucson, AZ, USA, 2Institute for Health and Productivity Management, Scottsdale, AZ, USA

PCN47

ACUTE LYMPHOCYTIC LEUKEMIA-RELATED INPATIENT CARE AMONG PEDIATRIC PATIENTS IN THE UNITED STATES

 

Mitra D, Candrilli SD
RTI Health Solutions, Research Triangle Park, NC, USA

PCN48

IMPACT ON HOSPITAL OUTPATIENT VISIT COSTS BY INITIATING PALONOSETRON VERSUS OTHER 5-HYDROXYTRYPTAMINE3 RECEPTOR ANTAGONISTS FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) AMONG PATIENTS WITH CANCER

 

Craver C1, Gayle J1, Balu S2, Buchner D2
1Premier, Inc., Charlotte, NC, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA

PCN49

THE RELATIONSHIP OF AGE AND SEX WITH COST OF TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA IN UKRAINE

 

Mandrik O, Zalis'ka O
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

PCN50

COST ANALYSIS OF DRG BASED FIRST LINE COLON CANCER THERAPIES IN HUNGARY

 

Valyi-Nagy I1, Jozsa G2
1Szt. Laszlo Korhaz, Budapest, Hungary, 2University of Western Hungary, Sopron, Hungary

PCN51

WITHDRAWN

 

 

PCN52

WILLINGNESS TO PAY AND COST BENEFIT ANALYSIS OF DELIVERY METHODS FOR DECISION SUPPORT FOR RURAL CANCER PATIENTS

 

Wilson LS1, Loucks A1, Franklin L1, O'Donnell S2, Moore D1, Jupiter C2, Kong S1, Yeung R1, Belkora J1
1University of California, San Francisco, San Francisco, CA, USA, 2Cancer Resource Centers of Mendocino County, Mendocino, CA, USA

PCN53

RISK OF PERSONAL BANKRUPTCY FOLLOWING A CANCER DIAGOSIS

 

Kirchhoff AC1, Fedorenko CR1, Snell K2, Blough DK3, Hollingworth W4, Ramsey S1
1Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA, 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 3University of Washington, Seattle, WA, USA, 4University of Bristol, Bristol, UK

PCN54

INJECTION OF LONG-ACTING SOMATOSTATIN ANALOGS: A COST CONSEQUENCE ANALYSIS IN FRANCE, GERMANY, THE UK AND THE UNITED STATES

 

Roze S1, Kurth H2, Maury le Breton A2
1HEVA, Lyon, France, 2IPSEN, Boulogne Billancourt, France

PCN55

RACIAL VARIATION IN THE COST-EFFECTIVENESS OF CHEMOTHERAPY FOR PROSTATE CANCER

 

Grabner M1, Onukwugha E1, Jain R2, Mullins CD1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Georgia College of Pharmacy, Athens, GA, USA

PCN56

COST-EFFECTIVENESS OF TEMSIROLIMUS FOR METASTIC RENAL-CELL CARCINOMA AND POOR PROGNOSIS PATIENTS IN MEXICO

 

Arreola-Ornelas H1, Rosado-Buzzo A2, Garcia-Mollinedo M2, Camacho L2, Mould-Quevedo JF3, Muciño-Ortega E4, Galindo-Suarez RM4
1Fundación Mexicana para la Salud AC, Mexico City, Mexico, 2Links & Links S.A, de C.V., Mexico City, Mexico, 3Pfizer, New York, NY, USA, 4Pfizer, Mexico City, Mexico

PCN57

ECONOMICS OF A MULTI-GENE ASSAY TO PREDICT RECURRENCE OF EARLY STAGE BREAST CANCER: EXPERIENCE OF A LARGE UNITED STATES INSURANCE PROGRAM

 

Hornberger J1, Chien R1, Kreb K2, Hochheiser LI2
1Cedar Associates LLC, Menlo Park, CA, USA, 2Humana, Inc., Louisville, KY, USA

PCN58

IS CYP2D6 GENETIC TEST IN COMBINATION WITH HORMONE THERAPY FOR ER+ HORMONE SENSITIVE WOMEN WITH EARLY BREAST CANCER COST-EFFECTIVE?

 

Djalalov S1, Beca J1, Hoch J2
1St. Michael's Hospital, Toronto, ON, Canada, 2Cancer Care Ontario, Toronto, ON, Canada

PCN59

COST EFFECTIVENESS ANALYSIS OF LAPATINIB/CAPECITABINE (LC) VERSUS TRASTUZUMAB/CAPECITABINE (TC) IN PATIENTS WITH METASTATIC BREAST CANCER ERBB2+ AFTER PROGRESSION TO THE FIRST SCHEME OF TRASTUZUMAB

 

Anaya P1, Aldaco F2
1GlaxoSmithKline, D.F., Mexico, 2GSK Mexico & National Medical Center 20 de Noviembre, D.F., Mexico

PCN60

COST-EFFECTIVENESS OF PEGFILGRASTIM VERSUS FILGRASTIM AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMA AND MYELOMA

 

Perrier L1, Lefranc A1, Quittet P2, Moreau P3, Siani C4, Ghesquières H1, Jardin F5, Favier B1, Ifrah N6, Lissandre S7, Pérol D1, Sebban C1
1Cancer Centre Leon Berard, Lyon, France, 2CHU Saint Eloi Montpellier, Montpellier, France, 3University Hospital, Nantes, France, 4University Claude Bernard Lyon 1, Lyon, France, 5Cancer Centre Henri Becquerel, Rouen, France, 6University Hospital Angers, Angers, France, 7CHU Tours - Hôpital Bretonneau, Tour, France

PCN61

COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER

 

Nguyen TTT1, Yagudina R2, Kulikov AU3
1First Moscow State Medical University named Sechenov, Moscow, Russia, 2Laboratory of Pharmacoeconomics, Moscow Medical Academy, Moscow, Russia, 3Moscow Medical Academy, Moscow, Russia

PCN62

BAYESIAN MODELLING ASSESSING THE EFFECTIVENESS OF A VACCINATION STRATEGY TO PREVENT HPV-RELATED DISEASES: THE BEST STUDY

 

Mennini FS1, Baio G2, Capone A3, Marcellusi A1, Favato G4, Costa S5, Garganese G6, Picardo M7, Drummond M8, Jonsson B9, Scambia G10, Zweifel P11
1University of Tor Vergata, Rome, Italy, 2University College London (UK), London, UK, 3University of Reading, Henley, UK, 4Kingston University, Kingston, UK, 5University of Bologna, Bologna, Italy, 6Catholic University of the Sacred Heart, Rome, Italy, 7San Gallicano Dermatological Institute (IRCCS), Rome, Italy, 8University of York, York, UK, 9Stockholm School of Economics, Stockholm, Sweden, 10University of the Sacred Heart, Rome, Italy, 11Zurich University, Zurich, Switzerland

PCN63

WITHDRAWN

 

 

PCN64

ECONOMIC EVALUATION OF THREE FORMULATIONS OF LEUPROLIDE ACETATE IN ANDROGEN DEPRIVATION THERAPY FOR ADVANCED PROSTATE CANCER IN BELGIUM

 

Wex J1, Sidhu M2, Odeyemi I2, Retsa P2
1PharmArchitecture Limited, London, UK, 2Astellas Pharma Europe, Staines, UK

PCN65

ECONOMIC EVALUATION OF THREE FORMULATIONS OF LEUPROLIDE ACETATE IN ANDROGEN DEPRIVATION THERAPY FOR ADVANCED PROSTATE CANCER IN PORTUGAL

 

Wex J1, Sidhu M2, Odeyemi I2, Retsa P2
1PharmArchitecture Limited, London, UK, 2Astellas Pharma Europe, Staines, UK

PCN66

COST-MINIMIZATION ANALYSIS OF THE USE OF RASBURICASE IN TUMOR LYSIS SYNDROME IN PEDIATRIC ONCOLOGY

 

Rodrigues AH1, Follador W2, Abadi M2, Petrilli AS3
1Instituto de Oncologia Pediatrica/Universidade Federal de Sao Paulo, São Paulo, Brazil, 2Sanofi-Aventis Farmaceutica Brazil, São Paulo, Brazil, 3Universidade Federal de Sao Paulo, São Paulo, Brazil

PCN67

ERCC1 EXPRESSION TESTING IN STAGE I NON-SMALL CELL LUNG CANCER: POTENTIAL CLINICAL AND ECONOMIC OUTCOMES

 

Roth J1, Carlson JJ2, Veenstra D1
1University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA

PCN68

AN ECONOMIC EVALUATION OF DASATINIB FOR THE TREATMENT OF IMATINIB REISTANT PATIENTS WITH CHRONIC MYELOGENOUS LEUKAEMIA

 

Taylor M1, Lewis L1, Lebmeier M2, Wang Q2
1York Health Economics Consortium, York, North Yorkshire, UK, 2Bristol-Myers Squibb, Uxbridge, Middlesex, UK

PCN69

AN ECONOMIC EVALUATION OF DASATINIB FOR THE TREATMENT OF IMATINIB RESISTANT PATIENTS WITH ADVANCED PHASE CHRONIC MYELOGENOUS LEUKAEMIA

 

Taylor M1, Lewis L1, Lebmeier M2, Wang Q2
1York Health Economics Consortium, York, North Yorkshire, UK, 2Bristol-Myers Squibb, Uxbridge, Middlesex, UK

PCN70

USING PHARMACOECONOMIC MODELING TO DETERMINE A VALUE-BASED PRICE OF NEW CANCER DRUGS IN MALAYSIA

 

Dranitsaris G1, Truter I1, Lubbe M2, Mahagaonkar S3
1Nelson Mandela Metropolitan University (NMMU), Port Elizabeth, Eastern Cape, South Africa, 2North-West University, Potchefstroom, North West Provi, South Africa, 3PharmARC Analytic Solutions, Bangalore, India

PCN71

USING MEASURES OF SOCIETAL VALUE AND ECONOMIC MODELING TO ESTIMATE PRICES FOR CANCER DRUGS IN SOUTH AFRICA

 

Dranitsaris G1, Truter I1, Lubbe M2, Fourie S3
1Nelson Mandela Metropolitan University (NMMU), Port Elizabeth, Eastern Cape, South Africa, 2North-West University, Potchefstroom, North West Provi, South Africa, 3Wilgers Oncology Center, Pretoria, Gauteng Province, South Africa

PCN72

GENE EXPRESSION PROFILING FOR GUIDING ADJUVANT CHEMOTHERAPY DECISIONS IN WOMEN WITH EARLY BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS OF 1000 STRATEGIES FOR THE PROVISION OF ADJUVANT! ONLINE, ONCOTYPE DX AND CHEMOTHERAPY

 

Paulden M1, Franek J2, Pham B1, Krahn M1
1University of Toronto, Toronto, ON, Canada, 2Ontario Ministry of Health and Long-Term Care, Toronto, ON, Canada

PCN73

UTILISATION OF ANTINEOPLASTIC AGENTS IN SLOVAK REPUBLIC

 

Gatialova K, Bellova K, Petrova L, Majtas J, Binder R
Comenius University, Bratislava, Slovak Republic

PCN74

UTILISATION OF DRUGS INVOLVED IN TREATMENT OF STAGE I AND STAGE II BREAST CANCER IN SLOVAK REPUBLIC

 

Gatialova K, Bellova K, Majtas J, Foltan V, Petrova L
Comenius University, Bratislava, Slovak Republic

PCN75

ECONOMIC EVALUATION OF DASATINIB IN CHRONIC MYELOGENOUS LEUKAEMIA PATIENTS RESISTANT TO IMATINIB IN PERU, COMPARED TO NILOTINIB AND HIGH DOSES OF IMATINIB

 

Orozco Giraldo JJ1, Valencia JE2, Garrido Lecca S3, Aiello EC4
1CES University, Medellin, Antioquia, Colombia, 2Bristol-Myers Squibb, Bogota, Colombia, 3Bristol-Myers Squibb, Lima, Peru, 4Bristol-Myers Squibb, Buenos Aires, Argentina

PCN76

SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES LEAD TO CONSIDERABLE HEALTH RESOURCE UTILISATION IN EUROPE: ANALYSIS OF A MULTINATIONAL OBSERVATIONAL STUDY

 

Hechmati G1, Hoefeler H2, Bahl A3, Lüftner D4, Lorusso V5, Garzón Rodriguez C6, Ashcroft J7, Suenaert P8, Wei R9, Durán I10
1Amgen (Europe) GmbH, Zug, Switzerland, 2Forschungszentrum Ruhr, Witten, Germany, 3University Hospitals Bristol, Bristol, UK, 4Universitätsmedizin Berlin, Berlin, Germany, 5Oncology Institute ASL, Lecce, Italy, 6Hospital Duran i Reynals, Barcelona, Spain, 7Pinderfields General Hospital, Wakefield, UK, 8Amgen Limited, Uxbridge, UK, 9Amgen, Inc., Thousand Oaks, California, USA, 10Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain

PCN77

USE OF SUBSTANCE ABUSE AMONG RESIDENTS OF KARACHI: REASONS AND COST OF USING SUBSTANCES

 

Parveen M
Aga Khan
University, Karachi, Sindh, Pakistan

PCN78

THE DEVELOPMENT OF A VALUE BASED PRICING INDEX FOR NEW DRUGS IN METASTATIC COLORECTAL CANCER

 

Dranitsaris G1, Truter I1, Lubbe M2
1Nelson Mandela Metropolitan University (NMMU), Port Elizabeth, Eastern Cape, South Africa, 2North-West University, Potchefstroom, North West Provi, South Africa

Cancer – Patient-Reported Outcomes & Preference-Based Studies

PCN79

IMPACT OF NON-ADHERENCE TO IMATINIB ON PROGRESSION-FREE SURVIVAL AS 1ST TREATMENT FOR CHRONIC MYELOID LEUKEMIA IN BRAZIL: TWO YEARS FOLLOW UP

 

Funke VAM1, Moellmann-Coelho A2, Asano E3, Nita ME3, Donato BM4, Rahal E3
1Hospital das Clínicas - UFPR, Curitiba, Brazil, 2Instituto Nacional do Câncer - INCA, Rio de Janeiro, Brazil, 3Bristol-Myers Squibb S/A, São Paulo, Brazil, 4Bristol-Myers Squibb, Wallingford, CT, USA

PCN80

PATIENT PREFERENCES FOR TOXICITIES ASSOCIATED WITH CHEMOTHERAPIES FOR ADVANCED BREAST CANCER

 

Beusterien K1, Grinspan J1, Tencer T2, Brufsky A3, Visovsky C4
1Oxford Outcomes Ltd., Bethesda, MD, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA, 3University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA, 4University of Nebraska Medical Center, Omaha, NE, USA

PCN81

DIVERSITY IN BELIEFS ABOUT THE CAUSES OF CANCER: A QUALITATIVE APPROACH TO EVALUATE CANCER PATIENTS' UNDERSTANDING TOWARDS CANCER AND ITS CAUSES

 

Farooqui M1, Hassali MA2, Knight A2, Shafie AA2, Tan BS3, Farooqui MA4
1Universiti Teknologi MARA, Penang, Malaysia, 2Universiti Sains Malaysia (USM), Penang, Malaysia, 3Penang General Hospital, Penang, Malaysia, 4Allianze College of Medical Sciences, Penang, Malaysia

PCN82

IMPACT OF OPTIMAL CML RESPONSE ON PATIENT SATISFACTION AND QUALITY OF LIFE: A PATIENT SURVEY FROM THE ASSOCIATION OF CANCER ONLINE RESOURCES (ACOR) DATABASE

 

Bollu V1, Niyazov A1, Huang Y2, Morlock R3, Guo A1, Goldberg SL4
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2Statistics SVC LLC, Fairfield, NJ, USA, 3i3 Innovus, Eden Prairie, MN, USA, 4John Theurer Cancer Center, Hackensack, NJ, USA

PCN83

A COMPARISON OF PREFERENCES FOR TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA

 

Park MH, Lee EK
Sookmyung Women's University, Seoul, South Korea

PCN84

PATIENTS' PREFERENCES FOR THE TREATMENT OF COLORECTAL CANCER: A DISCRETE CHOICE EXPERIMENT (DCE) SURVEY

 

Albassam A1, Noyce P2, Ashcroft D2
1Kuwait University, Kuwait, 2University of Manchester, Manchester, UK

PCN85

CANCER PATIENTS' PERCEPTION TOWARDS THE USE OF TRADITIONAL & COMPLEMENTARY MEDICINES (T&CM) FOR CANCER TREATMENT: A QUALITATIVE STUDY

 

Farooqui M1, Hassali MA2, Knight A2, Shafie AA2, Tan BS3, Farooqui MA4
1Universiti Teknologi MARA, Penang, Malaysia, 2Universiti Sains Malaysia (USM), Penang, Malaysia, 3Penang General Hospital, Penang, Malaysia, 4Allianze College of Medical Sciences, Penang, Malaysia

PCN86

A Q-TWIST ANALYSIS COMPARING PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) WITH BSC ALONE IN PATIENTS WITH WILD-TYPE KRAS METASTATIC COLORECTAL CANCER

 

Wang J1, Zhao Z2, Sherrill B1, Peeters M3, Wiezorek J2, Barber B2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Antwerp University Hospital, Edegem, Belgium

PCN87

HOW DOES PATIENT-REPORTED OUTCOME DATA INFLUENCE THE CLINICAL DECISION MAKING OF PRACTICING ONCOLOGISTS?

 

Meldahl ML1, Acaster S2, Hayes RP1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Oxford Outcomes Ltd., Oxford, UK

PCN88

ATTITUDES OF YOUNG WOMEN ON HUMAN PAPILLOMA VIRUS VACCINATION

 

Chopra P, Shah J, Fase B, Sansgiry S
University of Houston, Houston, TX, USA

PCN89

HTA AGENCIES' PREFERENCES REGARDING QUALITY OF LIFE MEASURES FOR PROSTATE CANCER CLINICAL TRIALS

 

Peeters P1, Casamayor M2, Moïse P1, Holmstrom S3
1Quintiles, Levallois-Perret, Ile-de-France, France, 2Quintiles, Barcelona, Spain, 3Astellas Pharma Europe, Leiderdorp, The Netherlands

PCN90

PRO INSTRUMENTS USED TO MEASURE SYMPTOM IMPACTS OF FATIGUE AND PAIN IN PROSTATE CANCER DRUGS TRIALS

 

Peeters P1, Casamayor M2, Moïse P1, Holmstrom S3
1Quintiles, Levallois-Perret, Ile-de-France, France, 2Quintiles, Barcelona, Spain, 3Astellas Pharma Europe, Leiderdorp, The Netherlands

PCN91

ARTHRALGIA AND PATIENT-REPORTED OUTCOMES IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER TAKING AROMATASE INHIBITORS: LONGITUDINAL ANALYSES

 

Castel LD1, Mayer IA1, Chen H1, McLellan SE1, Deppen SA1, Abramson VG1, Boomershine CS2, Friedman DL1, Gundy CM3, Lenderking WR4, Hartmann KE1, Johnson DH5, Cella DF6
1Vanderbilt University Medical Center, Nashville, TN, USA, 2Division of Rheumatology and Immunology, Vanderbilt University, Nashville, TN, USA, 3The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands, 4United BioSource Corporation, Lexington, MA, USA, 5University of Texas Southwestern Medical School, Dallas, TX, USA, 6Northwestern University, Chicago, IL, USA

PCN92

PSYCHOMETRIC COMPARISION OF THE EQ-5D-3L TO THE EQ-5D-5L IN CANCER PATIENTS IN KOREA

 

Kim SH, Jo MW
University of Ulsan College of Medicine, Seoul, South Korea

PCN93

ATTACHMENT STYLE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PROSTATE CANCER

 

Sansgiry S1, Hart SL2, Coon DW3, Siffert KJ4, Latini DM1
1VA HSR&D Center of Excellence Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, USA, 2Ryerson University, Toronto, ON, Canada, 3Arizona State University, Phoenix, AZ, USA, 4University of Houston, Houston, TX, USA

PCN94

HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN 1ST LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN A REAL LIFE SETTING: BEVACIZUMAB-BASED VERSUS NON-BEVACIZUMAB BASED THERAPY IN A EUROPEAN PILOT STUDY

 

Chouaid C1, Bischoff HG2, Vergnenegre A3, Heigener DF4, Taylor-Stokes G5, Roughley A5, Walzer S6
1Hôpital Saint Antoine, Paris , France, 2Thoraxklinik Heidelberg GmbH, Hedelberg, Germany, 3SIME, Limoges, France, 4Krankenhaus Grosshansdorf, Grosshansdorf, Germany, 5Adelphi Real World, Macclesfield, Cheshire, UK, 6F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland

PCN95

A SYSTEMATIC REVIEW OF QUALITY OF LIFE INSTRUMENTS IN LONG TERM BREAST CANCER SURVIVORS

 

Chopra I1, Kamal KM2
1Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA, 2Duquesne University, Pittsburgh, PA, USA

PCN96

CANCER PATIENT PREFERENCES AND WILLINGNESS TO PAY FOR PREVENTING CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN THE UNITED STATES

 

Miller PJ1, Balu S2, Buchner D2, Walker MS1, Stepanski EJ1, Schwartzberg LS3
1ACORN Research, LLC, Memphis, TN, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA, 3West Clinic, Memphis, TN, USA

Cancer – Health Care Use & Policy Studies

PCN97

IMPACT OF GLOBAL HEALTH CARE REFORMS ON PRICING, ACCESS AND HEALTH ECONOMICS AND OUTCOMES STRATEGY

 

Aggarwal S
PAREXEL Consulting, Bethesda, MD, USA

PCN98

WITHDRAWN

 

 

PCN99

ITALIAN MONITORING REGISTRY OF BEVACIZUMAB IN THE TREATMENT OF METASTATIC COLON RECTAL CARCINOMA

 

Siviero PD, Montilla S, De Nigro L, Foggi P, Tomino C, Rasi G
Italian Medicines Agency (AIFA), Rome, Italy

PCN100

RACIAL DISPARITIES IN AFRICAN-AMERICAN VERSUS WHITE WOMEN WITH NEWLY DIAGNOSED BREAST CANCER IN A SOUTHEAST UNITED STATES HEALTH PLAN

 

Fisher M1, Cai Q1, Paoli CJ2, Lyons A3, Wasser T1, Rodriguez N4, White S5, Kallich J3, Barron J1, Brawley OW6
1HealthCore, Inc., Wilmington, DE, USA, 2University of California, San Francisco, San Francisco, CA, USA, 3Amgen, Inc., Thousand Oaks, CA, USA, 4Blue Cross Blue Shield of Georgia, Atlanta, GA, USA, 5WellPoint, Atlanta, GA, USA, 6American Cancer Society, Atlanta, GA, USA

PCN101

HEALTH CARE RESOURCE UTILIZATION AND ECONOMIC BURDEN OF METASTATIC AND RECURRENT LOCALLY-ADVANCED HEAD AND NECK CANCER PATIENTS

 

Le TK1, Winfree KB1, Yang H2, Marynchenko M2, Yu AP2, Frois C2, Wu EQ2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Analysis Group, Inc., Boston, MA, USA

PCN102

SYNCHRONIZATION OF ADMINISTRATIONS OF CHEMOTHERAPY AND ERYTHROPOIESIS-STIMULATING AGENTS AND FREQUENCY OF ASSOCIATED HEALTH CARE VISITS

 

Hill J1, Shreay S2, McGarvey N2, De AP1, Hess GP1, Corey-Lisle P2
1SDI Health, Plymouth Meeting, PA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA

PCN103

THE IMPACT OF INFUSION REACTIONS ASSOCIATED WITH MONOCLONAL ANTIBODIES IN METASTATIC COLORECTAL CANCER: A EUROPEAN PERSPECTIVE

 

Chadda S1, Larkin M1, Jones C1, Sykes D1, Barber B2, Zhao Z2, Gao S2, Bengttson NO3
1PRMA Consulting, Fleet, UK, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Norrlands Universitetssjukhus, Umeå, Sweden

PCN104

HOSPITAL COSTS OF ADVERSE EVENTS IN PATIENTS RECEIVING TREATMENT FOR METASTATIC COLORECTAL CANCER

 

Fu AZ1, Zhao Z2, Wang S2, Gao S2, Barber B2, Liu G3
1Cleveland Clinic, Cleveland, OH, USA, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Peking University, Beijing, China

PCN105

ESTIMATING NICE'S COST EFFECTIVE THRESHOLD FOR END-OF-LIFE CANCER TREATMENTS

 

Moïse P1, Fassler P2
1Quintiles, Levallois-Perret, Ile-de-France, France, 2Quintiles, Hoofddorp, The Netherlands

PCN106

RESEARCH ON THE FACTORS AFFECTING THE ADOPTION OF HIGH VALUE MEDICAL CONSUMES IN LESS DEVELOPED AREAS OF CHINA

 

Jing W, Guanglian X
Huazhong University of Science and Technology, Wuhan, Hubei, China

PCN107

PAYER-RATED VALUE OF PAIN IMPROVEMENT IN CASTRATION-RESISTANT PROSTATE CANCER: TRADEOFFS BETWEEN SURVIVAL, PAIN AND ANALGESIC USE

 

Schneider J1, Beusterien K2, Ohsfeldt R3, Brown J4, Boye ME5, Ebeid O1, Hill J5
1Oxford Outcomes Ltd., Morristown, NJ, USA, 2Oxford Outcomes Ltd., Bethesda, MD, USA, 3Texas A&M Health Science Center, College Station, TX, USA, 4Eli Lilly and Company, Windlesham, Surrey, UK, 5Eli Lilly and Company, Indianapolis, IN, USA

PCN108

CLINICAL EFFICACY AND ONCOLOGY REIMBURSEMENT RECOMMENDATIONS IN CANADA BY THE INTERIM JOINT ONCOLOGY DRUG REVIEW (IJODR)

 

Ciapanna CC1, Shum D2, Milliken D2, Yunger S2
1McMaster University, Burlington, ON, Canada, 2Hoffmann-La Roche Limited, Mississauga, ON, Canada

PCN109

TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION OF METASTATIC PROSTATE CANCER PATIENTS BY PHYSICIAN SPECIALTY

 

Senbetta M1, Lafeuille MH2, Dean J2, McKenzie RS1, Lefebvre P2
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Groupe d'analyse, Ltée, Montreal, QC, Canada

PCN110

REAL WORLD CLINICAL RESOURCE UTILIZATION OF METASTATIC PROSTATE CANCER PATIENTS IN THE UNITED STATES: RESULTS FROM TWO LARGE CLAIMS DATABASES

 

Lafeuille MH1, Senbetta M2, McKenzie RS2, Lefebvre P1
1Groupe d'analyse, Ltée, Montreal, QC, Canada, 2Centocor Ortho Biotech Services, LLC, Horsham, PA, USA

PCN111

ANALYSIS OF HEALTH OUTCOMES IN BREAST CANCER PATIENTS USING CLUSTER ANALYSIS

 

Ugiliweneza B
University of Louisville, Louisville, KY, USA

PCN112

COMPARISON OF CHARACTERISTICS OF COLORECTAL CANCER PATIENTS ADMITTED EMERGENTLY, URGENTLY OR ELECTIVELY IN WEST VIRGINIA HOSPITALS BETWEEN 2003-2007

 

Shah N, Halverson J
West Virginia University, Morgantown, WV, USA

PCN113

LEARNING THE LESSONS OF ONCOLOGY HTA REVIEWS IN AUSTRALIA & THE UK – A CASE STUDY OF FIVE DRUGS

 

Lewis S, Dummett H
Double Helix Consulting, London, UK

PCN114

DEVELOPING A FAMILIAL CANCER RISK ASSESSMENT TOOL FOR USE IN UNDERSERVED COMMUNITIES

 

Bhattacharjee S1, Westman JA2, Kelly KM1
1West Virginia University, Morgantown, WV, USA, 2Ohio State University, Columbus, OH, USA

PCN115

A CROSS-COUNTRY COMPARISON OF SECOND-LINE MULTIPLE MYELOMA TREATMENTS

 

Walker SA, Izmirlieva MA, Mehta P
IHS Global Insight, London, UK

PCN116

TRANSFERABILITY OF NICE RECOMMENDATIONS FOR PHARMACEUTICAL THERAPIES IN ONCOLOGY TO CENTRAL-EASTERN EUROPEAN COUNTRIES

 

Kalo Z1, Landa K2, Dolezal T3, Vokó Z1
1Eötvös Loránd University, Budapest, Hungary, 2HTA Audit, Krakow, Poland, 3Institute for Health Economics and Technology Assessment, Prague, Czech Republic

PCN117

ASSOCIATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH ISS STAGE AND ECOG STATUS IN MULTIPLE MYELOMA

 

Pashos CL1, Durie BG2, Mehta J3, Toomey K4, Terebelo HR5, Abonour R6, Fonseca R7, Gasparetto C8, Narang M9, Rifkin RM10, Shah JJ11, Sullivan KA12, Street TK13, Khan ZM13
1United BioSource Corporation, Lexington, MA, USA, 2Cedar Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USA, 3Northwestern University, Chicago, IL, USA, 4Steeplechase Cancer Center, Somerville, NJ, USA, 5Providence Cancer Institute, Southfield, MI, USA, 6Indiana University Simon Cancer Center, Indianapolis, IN, USA, 7Mayo Clinic Arizona, Scottsdale, AZ, USA, 8Duke University Medical Center, Durham, NC, USA, 9Alliance Hematology Oncology, Westminister, MD, USA, 10Rocky Mountain Cancer Centers, Denver, CO, USA, 11University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA, 12Celgene Corporation, Overland Park, KS, USA, 13Celgene Corporation, Summit, NJ, USA

PCN118

PREDICTING THE FUTURE IMPACT OF EMERGING TECHNOLOGIES ON HEPATOCELLULAR CARCINOMA (HCC): MEASURING STAKEHOLDERS PREFERENCES WITH BEST-WORST SCALING

 

Gallego G1, Bridges JF1, Flynn T2, Blauvelt BM3
1Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA, 2University of Technology Sydney, Sydney, NSW, Australia, 3University of Massachusetts, Hadley, MA, USA

PCN119

VALIDATION OF A NEW MEASURE OF PATIENT EMPOWERMENT IN ONCOLOGY: FIVE HEALTH EDUCATION IMPACT QUESTIONNAIRE (HEIQ) SCALES

 

Maunsell E1, Lauzier S1, Brunet J2, Campbell S3, Elsworth G4, Osborne RH4
1Université Laval, Québec, QC, Canada, 2McGill University, Montreal, QC, Canada, 3University of Waterloo, Waterloo, ON, Canada, 4Deakin University, Melbourne, Victoria, Australia

PCN120

WHO CHOSE PRIMARY ANDROGEN DEPRIVATION THERAPY OVER RADICAL PROSTATECTOMY: A RETROSPECTIVE STUDY AMONG VETERANS WITH LOCALIZED PROSTATE CANCER

 

Liu J, Shi L, Sartor O
Tulane University, New Orleans, LA, USA

PCN121

ONCOLOGY MEDICATION UTILIZATION BASED ON FEDERAL DRUG ADMINISTRATION (FDA) LABELING, NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) CLINICAL PRACTICE GUIDELINE (GL) RECOMMENDATIONS, AND EVIDENCE FOR PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER (NSCLC): AN ANALYSIS FROM THE NCCN ONCOLOGY OUTCOMES DATABASE

 

Lepisto EM1, Vandergrift JL1, Kalemkerian GP2, Pisters KM3, Zornosa C1, Rabin MS4, Reid ME5, Koczywas M6, Otterson GA7, Ettinger DS8
1National Comprehensive Cancer Network, Fort Washington, PA, USA, 2University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA, 3The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 4Dana-Farber Cancer Institute, Boston, MA, USA, 5Roswell Park Cancer Institute, Buffalo, NY, USA, 6City of Hope National Medical Center, Duarte, CA, USA, 7Ohio State University, Columbus, OH, USA, 8The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

PCN122

MELODY BRAZIL: CHEMOTHERAPY CHOICES FOR PATIENTS WITH METASTATIC MELANOMA IN THE PUBLIC HEALTH CARE SYSTEM (SUS)

 

Schmerling RA1, Stefani SD2, Barbosa E3, Asano E3, Nita ME3, Nishikawa AM3, Dias KM4, Donato BM5, Rahal E3, MELODY Brasil Study Grou P3
1Instituto do Câncer do Estado de São Paulo – “Octávio Frias de Oliveira” – ICESP, São Paulo, SP, Brazil, 2Hospital Mãe de Deus, Porto Alegre, RS, Brazil, 3Bristol-Myers Squibb S/A, São Paulo, SP, Brazil, 4NEW BD - Business Developers, São Paulo, SP, Brazil, 5Bristol-Myers Squibb, Wallingford, CT, USA

PCN123

A SYSTEMATIC REVIEW OF TREATMENT GUIDELINES FOR METASTATIC COLORECTAL CANCER

 

Edwards M1, Chadda S1, Zhao Z2, Barber B2, Sykes D1
1PRMA Consulting, Fleet, UK, 2Amgen, Inc., Thousand Oaks, CA, USA

PCN124

CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF CHRONIC MYELOGENOUS LEUKEMIA PATIENTS TREATED AT PUBLIC ONCOLOGY CLINICS IN SÃO PAULO, BRAZIL

 

Takemoto ML, Takemoto MMS, Fernandes RA, Tolentino ACM, Santos PML
ANOVA - Knowledge Translation, Rio de Janeiro, Brazil

PCN125

MELODY BRASIL: TREATMENT PATTERNS AND ASSOCIATED COSTS OF METASTATIC MELANOMA PATIENTS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM (SUS)

 

Stefani S1, Schmerling RA2, Asano E3, Nita ME3, Nishikawa AM3, Dias KM4, Donato BM5, Rahal E3, MELODY Brasil Study Grou P3
1Hospital Mãe de Deus, Porto Alegre, RS, Brazil, 2Instituto do Câncer do Estado de São Paulo – “Octávio Frias de Oliveira” – ICESP, São Paulo, SP, Brazil, 3Bristol-Myers Squibb S/A, São Paulo, SP, Brazil, 4NEW BD - Business Developers, São Paulo, SP, Brazil, 5Bristol-Myers Squibb, Wallingford, CT, USA

Cancer – Research on Methods

PCN126

OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE

 

Heron L1, De Castro Carpeño J2, Chouaid C3, Vergnenègre A4, Bischoff HG5, Walzer S6
1MAPI Values, Macclesfield, Cheshire, UK, 2Hospital Universitario de La Paz, Madrid, Spain, 3Hôpital Saint Antoine, Paris, France, 4SIME, Limoges, France, 5Thoraxklinik Heidelberg GmbH, Hedelberg, Germany, 6F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland

PCN127

METHODS FOR INDIRECT COMPARISON OF EFFECTIVENESS IN COST-EFFECTIVENESS ANALYSES OF ONCOLOGY AGENTS: THE PROPORTIONAL HAZARDS ASSUMPTION MATTERS

 

Ducournau P1, Zhao Z2, Barber B2, Gao S2, Graham CN3
1Amgen (Europe) GmbH, Zug, Switzerland, 2Amgen, Inc., Thousand Oaks, CA, USA, 3RTI Health Solutions, Research Triangle Park, NC, USA

PCN128

LINKING MEDICARE, MEDICAID AND CANCER REGISTRY DATA TO STUDY BURDEN OF CANCERS IN WEST VIRGINIA (FUNDING: AHRQ - R24 HS018622-01)

 

Nadpara P, Madhavan S
West Virginia University, Morgantown, WV, USA

PCN129

USE OF ELECTRONIC MEDICAL RECORDS (EMR) FOR ONCOLOGY OUTCOMES RESEARCH: ASSESSING THE COMPARABILITY OF EMR INFORMATION TO PATIENT REGISTRY AND HEALTH CLAIMS DATA

 

Lau EL1, Mowat FS1, Kelsh MA1, Legg J2, Engel-Nitz NM3, Watson HN1, Collins H2, Nordyke RJ4, Whyte JL2
1Exponent, Menlo Park, CA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA, 3i3 Innovus, Eden Prairie, MN, USA, 4PriceSpective LLC, El Segundo, CA, USA

PCN130

RECORD-LINKAGE FOR PHARMACOEPIDEMIOLOGIC STUDIES IN CANCER PATIENTS

 

van Herk-Sukel MPP1, Lemmens V2, van de Poll L3, Herings RMC1, Coebergh JW4
1PHARMO Institute, Utrecht, The Netherlands, 2Comprehensive Cancer Center, Eindhoven, The Netherlands, 3Comprehensive Cancer Center South, Eindhoven, The Netherlands, 4Erasmus University Medical Center, Rotterdam, The Netherlands

PCN131

REPRESENTING UNCERTAINTY IN CALIBRATED CANCER TREATMENT MODELS: A PRACTICAL APPROACH

 

Taylor DC1, Leahy KJ1, Weinstein M2
1i3 Innovus, Medford, MA, USA, 2Harvard School of Public Health, Boston, MA, USA

PCN132

MODELING THE LIFETIME EFFECTIVENESS OF DENOSUMAB AND ZOLEDRONIC ACID (ZA) IN THE PREVENTION OF SKELETAL RELATED EVENTS (SRE) IN PATIENTS WITH BONE METASTASES FROM SOLID TUMORS

 

Danese MD1, Bracco A2, Macarios D3, Chung K3, Barlev A3, Halperin M1, Lothgren M2
1Outcomes Insights, Inc., Westlake Village, CA, USA, 2Amgen (Europe) GmbH, Zug, Switzerland, 3Amgen, Inc., Thousand Oaks, CA, USA

PCN133

ESTIMATING THE EPIDEMIOLOGY OF LATE-STAGE CANCERS – A MATHEMATICAL APPROACH

 

Pan F, Sorensen S, Stern S
United BioSource Corporation, Bethesda, MD, USA

PCN134

HUMANISTIC CONSEQUENCES OF PREVENTABLE BLADDER TUMOR RECURRENCES IN NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

 

Barocas DA1, Globe D2, Colayco D2, Gilmore A3, Bramley T3
1Vanderbilt University Medical Center, Nashville, TN, USA, 2Allergan, LLC, Irvine, CA, USA, 3Xcenda, LLC., Palm Harbor, FL, USA

PCN135

ECONOMIC CONSEQUENCES OF PREVENTABLE BLADDER TUMOR RECURRENCES IN NON-MUSCLE INVASIVE BLADDER CANCER

 

Lee CT1, Globe D2, Colayco D2, Gilmore A3, Bramley T3
1University of Michigan, Ann Arbor, MI, USA, 2Allergan LLC, Irvine, CA, USA, 3Xcenda, LLC., Palm Harbor, FL, USA

PCN136

ESTIMATING UTILITIES IN CANCER: A COMPARISON OF EQ-5D AND FACT-BASED ALGORITHMS

 

Pickard AS1, Ganguli A2, Ray S2, Cella D3
1University of Illinois at Chicago, Chicago, IL, USA, 2Abbott Laboratories, Abbott Park, IL, USA, 3Northwestern University, Chicago, IL, USA

PCN137

COMPREHENSIVE REVIEW OF MANAGEMENT EFFICIENCY STRATEGIES AMONG ONCOLOGY PRACTICES: EXISTING EVIDENCE AND OPPORTUNITIES FOR FUTURE RESEARCH

 

Gorman K1, Miller R1, McGarvey N2, Corey-Lisle P3
1Cerner LifeSciences, Beverly Hills, CA, USA, 2UCLA School of Public Health, Los Angeles, CA, USA, 3Amgen, Inc., Thousand Oaks, CA, USA

PCN138

A REVIEW OF EXPANDED ACCESS PROGRAMS (EAP) AND THEIR CONSIDERATION BY HEALTH PLAN DECISION-MAKERS IN THE UNITED STATES

 

Khurdayan V, Rizzo M, Darity A, Mun D
Double Helix Consulting, New York, NY, USA

POSTER PRESENTATIONS SESSION III
SET-UP: Wednesday, May 25, 2011 - 7:30AM – 8:00AM
POSTER DISPLAY HOURS: Wednesday, May 25, 2011 - 8:00AM – 3:00PM
POSTER AUTHOR DISCUSSION HOUR: Wednesday, May 25, 2011 - 11:45AM - 12:45PM
DISMANTLE: Wednesday, May 25, 2011 - 3:00PM – 3:30PM

Gastrointestinal Disorders – Clinical Outcomes Studies

PGI1

INCIDENCE OF ANEMIA AND NEUTROPENIA FOLLOWING HCV TREATMENT INITIATION AND RELATED DRUG TREATMENT COSTS IN THE UNITED STATES

 

Diels J, Gavart S, Nuyts G
Janssen Pharmaceutica, Beerse, Belgium

PGI2

PREDICTORS OF PROTON PUMP INHIBITOR (PPI) DOSING REGIMEN AMONG PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD)

 

Eisenberg D1, Mody R2, Singer J1, Kamat SA1, Gerson LB3
1HealthCore, Inc., Wilmington, DE, USA, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, 3Stanford University, Palo Alto, CA, USA

PGI3

THE LIKELIHOOD OF HAVING FUNCTIONAL DYSPEPSIA BASED ON OTHER COMORBID CONDITIONS

 

Brook RA1, Talley NJ2, Choung RS3, Smeeding J4, Kleinman NL5
1The JeSTARx Group, Newfoundland, NJ, USA, 2University of Newcastle, Callaghan, NSW, Australia, 3Mayo Clinic, Rochester, MN, USA, 4JeSTARx Group, Dallas, TX, USA, 5HCMS Group, Paso Robles, CA, USA

PGI4

PREDICTORS OF HEPATITIS C TREATMENT INITIATION

 

Wagner JS, Goren A
Kantar Health, New York, NY, USA

PGI5

COMPARISON OF HEALTH CARE UTILIZATIONS BETWEEN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE WHO SWITCHED FROM A BRANDED PROTON PUMP INHIBITOR TO A GENERIC PROTON PUMP INHIBITOR AND VICE VERSA

 

Xie L, Baser E, Wang L, Baser O
STATinMED Research, Ann Arbor, MI, USA

Gastrointestinal Disorders – Cost Studies

PGI6

THE ECONOMIC BURDEN OF ADVANCED LIVER DISEASE AMONG PATIENTS WITH HEPATITIS C VIRUS: A STATE MEDICAID PERSPECTIVE

 

Menzin J1, White LA1, Nichols C1, Deniz B2
1Boston Health Economics, Inc., Waltham, MA, USA, 2Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA

PGI7

THE ECONOMIC BURDEN OF REFRACTORY GERD: A RESTROSPECTIVE CLAIMS DATABASE STUDY

 

Gerson LB1, Bonafede M2, Princic N3, Gregory C4, Farr A4, Chu BC5, Balu S6
1Stanford University, Palo Alto, CA, USA, 2Thomson Reuters, Andover, MA, USA, 3Thomson Reuters, Cambridge, MA, USA, 4Thomson Reuters, Washington, DC, USA, 5Thomson Reuters, Santa Barbara, CA, USA, 6Eisai, Inc., Woodcliff Lake, NJ, USA

PGI8

COMPARING HEALTH-RISK BURDEN, LOST PRODUCTIVITY, AND TOTAL HEALTHCARE COSTS AMONG INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE AND FIVE MOST PREVALENT CHRONIC DISEASES

 

Naim A1, Pitts J2, Chen CY3, Wright D3, Chalk MB2, Edington D3
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Chalk & Associates, Austin, TX, USA, 3University of Michigan, Ann Arbor, MI, USA

PGI9

COMPARISON OF DIRECT MEDICAL COSTS AND SERVICES BY POINT OF SERVICE AND PRESCRIPTION COST FOR PERSONS WITH HEPATITIS-C WITH AND WITHOUT TREATMENT

 

Brook RA1, Kleinman NL2, Smeeding J3
1The JeSTARx Group, Newfoundland, NJ, USA, 2HCMS Group, Paso Robles, CA, USA, 3JeSTARx Group, Dallas, TX, USA

PGI10

EXAMINATION OF RESOURCE UTILIZATION PATTERNS ACROSS SUBGROUPS OF GASTROESOPHAGEAL REFLUX DISEASE PATIENTS

 

Gerson LB1, Balu S2, McLaughlin T3, Lunacsek O3, Jackson J3
1Stanford University, Palo Alto, CA, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA, 3Xcenda, LLC., Palm Harbor, FL, USA

PGI11

THE ECONOMIC AND QUALITY OF LIFE BURDEN OF ILLNESS IN CHRONIC CONSTIPATION (CC) AND IRRITABLE BOWEL SYNDROME (IBS): A SYSTEMATIC REVIEW

 

Yee K1, Nellesen D1, Chawla A1, Carson R2, Lewis B3
1Analysis Group, Inc., Menlo Park, CA, USA, 2Forest Research Institute, Jersey City, NJ, USA, 3Ironwood Pharmaceuticals, Cambridge, MA, USA

PGI12

DOSE VARIATIONS WITH ADALIMUMAB AND INFLIXIMAB IN THE TREATMENT OF CROHN'S DISEASE: A CANADIAN ASSESSMENT

 

Lachaine J1, Beauchemin C1, Goyette A2, Martel MJ2
1University of Montreal, Montreal, QC, Canada, 2Abbott Laboratories, St-Laurent, QC, Canada

PGI13

PERCEIVED VALUE ASSESSMENT OF ENTECAVIR VERSUS NO TREATMENT IN CHRONIC HEPATITIS B

 

Vorobyev P1, Telegina I2, Borisenko O1, Jakouloff D3
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2Stavropol State Medical Academy, Stavropol, Russia, 3BMS, Moscow, Russia

PGI14

PERCEIVED VALUE ASSESSMENT OF ENTECAVIR VERSUS TENOFOVIR IN CHRONIC HEPATITIS B

 

Vorobyev P1, Telegina I2, Borisenko O1, Jakouloff D3
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2Stavropol State Medical Academy, Stavropol, Russia, 3BMS, Moscow, Russia

PGI15

COST EFFECTIVENES OF THE PHARMACOLOGIC TREATMENT OF IRRITABLE BOWEL SYNDROME AT THE SOCIAL SECURITY MEXICAN INSTITUTE

 

Ojeda Méndez J1, Contreras I2, Vallejos Parás A1
1Universidad Nacional Autónoma de México, México City, Mexico, 2Instituto Mexicano del Seguro Social, México City, Mexico

PGI16

RESOURCE UTILIZATION AND HEALTH CARE COSTS ASSOCIATED WITH DIVERTICULAR DISEASE: RESULTS FROM A RETROSPECTIVE CLAIMS DATABASE ANALYSIS IN THE UNITED STATES

 

Yen L1, Davis K2, Longstreth G3, Streck P1, Hodgkins P1
1Shire Pharmaceuticals, Wayne, PA, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Kaiser Permanente, San Diego, CA, USA

Gastrointestinal Disorders – Patient-Reported Outcomes & Preference-Based Studies

PGI17

HCV TREATMENT CONTINUATION RATES IN GENOTYPE 1 PATIENTS IN A REAL-WORLD SETTING IN THE UNITED STATES

 

Diels J, Gavart S, Nuyts G
Janssen Pharmaceutica, Beerse, Belgium

PGI18

FEASIBILITY OF ASSESSING UTILITY BY EQ-5D AND TIME-TRADE-OFF METHODS IN TAIWANESE CHRONIC HEPATITIS B PATIENTS

 

Lin YT1, Chen LC2, Huang YB1, Huang JF3
1Kaohsiung Medical University, Kaohsiung, Taiwan, 2University of Nottingham, Nottingham, UK, 3Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

PGI19

HEALTH-RELATED QUALITY OF LIFE IS LOWER FOR PATIENTS WITH DIURNAL AND NOCTURNAL GERD SYMPTOMS

 

Goren A1, Gupta S2, Balu S3, Buchner D3
1Kantar Health, New York, NY, USA, 2Kantar Health, Princeton, NJ, USA, 3Eisai, Inc., Woodcliff Lake, NJ, USA

PGI20

IBS-C PATIENT SYMPTOM REPORTS: ANALYSIS OF EXPLORATORY OPEN-ENDED QUESTIONS

 

Carson RT1, Lewis BE2, Shiff SJ1, Johnston JM2, Dennee-Sommers B3, Lasch KE3, Hwang S3, Marquis P3
1Forest Research Institute, Jersey City, NJ, USA, 2Ironwood Pharmaceuticals, Cambridge, MA, USA, 3MAPI Values, Boston, MA, USA

PGI21

HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MILD-TO-MODERATE ULCERATIVE COLITIS BEFORE AND AFTER 8 WEEKS' TREATMENT WITH MULTI-MATRIX MESALAMINE: COMPARISON WITH 2009 GENERAL POPULATION NORMS IN THE UNITED STATES

 

Yarlas A1, Yen L2, Hodgkins P2
1QualityMetric Incorporated, Lincoln, RI, USA, 2Shire Pharmaceuticals, Wayne, PA, USA

PGI22

CONCORDANCE AMONG MULTIPLE HEALTH OUTCOMES MEASURES IN RESPONSIVENESS TO MULTI-MATRIX MESALAMINE MAINTENANCE TREATMENT FOR PATIENTS WITH QUIESCENT ULCERATIVE COLITIS

 

Yen L1, Yarlas A2, Hodgkins P1
1Shire Pharmaceuticals, Wayne, PA, USA, 2QualityMetric Incorporated, Lincoln, RI, USA

PGI23

WORK PRODUCTIVITY AMONG GENOTYPE 1 HEPATITIS C VIRUS (HCV) TREATMENT-NAÏVE PATIENTS RECEIVING TELAPREVIR-BASED TREATMENT REGIMENS: RESULTS FROM ADVANCE AND ILLUMINATE STUDIES

 

Thal G1, Nuyts G2, Mcallister S1, Luo D3, Muir AJ4, Sherman KE5, Adda N1, Wright C1, Beumont M6, Gavart S2
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA, 2Janssen Pharmaceutica, Beerse, Belgium, 3Tibotec Inc., Titusville, NJ, USA, 4Duke University Medical Center, Durham, NC, USA, 5University of Cincinnati College of Medicine, Cincinnati, OH, USA, 6Tibotec BVBA, Beerse, Belgium

PGI24

DOES UTILITY OR CAPABILITY MATTER FOR IRRITABLE BOWEL SYNDROME? - A PRELIMINARY QUALITATIVE STUDY ON TAIWANESE PATIENTS

 

Hsu CC1, Chen LC2, Wen YH1, Su YC3
1Kaohsiung Medical University, Kaohsiung, Taiwan, 2University of Nottingham, Nottingham, UK, 3Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan

Gastrointestinal Disorders – Health Care Use & Policy Studies

PGI25

STRUCTURED MANAGEMENT STRATEGY VERSUS USUAL PRIMARY CARE FOR GASTROESOPHAGEAL REFLUX DISEASE: META-ANALYSIS OF FIVE EUROPEAN CLUSTER RANDOMIZED TRIALS ASSESSING HEALTH CARE UTILIZATION COSTS

 

Ponce J1, Garrigues V1, Hatlebakk JG2, Agréus L3, Tabaglio E4, Gschwantler M5, Guallar E6, Tafalla M7, Nuevo J7
1Hospital Universitario La Fe, CIBERehd, Valencia, Spain, 2University of Bergen, Bergen, Norway, 3Karolinska Institute, Stockholm, Sweden, 4Società Italiana Medicina Generale, Firenze, Italy, 5Wilhelminenspital, Wien, Austria, 6Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD, USA, 7AstraZeneca, Madrid, Spain

PGI26

PATIENT CHARACTERISTICS ASSOCIATED WITH USE OF ENTERAL VERSUS PARENTERAL ACID SUPPRESSIVE AGENTS IN INTENSIVE CARE UNIT PATIENTS

 

Sankaranarayanan J, Reardon T, Olsen KM
University of Nebraska Medical Center, Omaha, NE, USA

POSTER PRESENTATIONS SESSION III
SET-UP: Wednesday, May 25, 2011 - 7:30AM – 8:00AM
POSTER DISPLAY HOURS: Wednesday, May 25, 2011 - 8:00AM – 3:00PM
POSTER AUTHOR DISCUSSION HOUR: Wednesday, May 25, 2011 - 11:45AM - 12:45PM
DISMANTLE: Wednesday, May 25, 2011 - 3:00PM – 3:30PM

Mental Health – Clinical Outcomes Studies

PMH1

IS STIMULANT OR ATOMOXETINE UTILIZATION ASSOCIATED WITH NEUROLOGICAL ADVERSE EVENTS IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)? A RETROSPECTIVE ANALYSIS OF PROPENSITY SCORE MATCHED DATA

 

Bhattacharjee S1, Chen H2, Bhatara V3, Aparasu RR2
1West Virginia University, Morgantown, WV, USA, 2University of Houston, Houston, TX, USA, 3University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USA

PMH2

RISK OF HOSPITALIZATION FOR PNEUMONIA ASSOCIATED WITH THE USE OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTICS IN A NATIONAL SAMPLE OF MEDICARE BENEFICIARIES

 

Dharmarajan SH, Yang Y, Athavale AS, Bentley JP, Null KD, Banahan BF
University of Mississippi, University, MS, USA

PMH3

RISK OF HIP FRACTURES IN ELDERLY MEDICARE BENEFICIARIES USING ATYPICAL OR TYPICAL ANTIPSYCHOTICS: A PROPENSITY SCORE ANALYSIS

 

Dharmarajan SH, Yang Y, Athavale AS, Bentley JP, Null KD, Banahan BFI
University of Mississippi, University, MS, USA

PMH4

RISK OF FALLS AND FRACTURES IN OLDER ADULTS USING ATYPICAL ANTIPSYCHOTICS-A MULTIPLE PROPENSTY SCORE ADJUSTED RETROSPECTIVE COHORT STUDY

 

Chatterjee S, Chen H, Johnson ML, Aparasu RR
University of Houston, Houston, TX, USA

PMH5

PSYCHIATRIC ADVERSE EFFECTS RELATED TO PRESCRIPTION OF METHYLPHENIDATE IN TAIWAN

 

Yang CL1, Huang WF2, Tsai YW1
1Institute of Health & Welfare Policy, National Yang-Ming University, Taipei, Taiwan, 2National Yang-Ming University, Taipei, Taiwan

PMH6

DIFFERENTIAL RATES OF SIDE EFFECTS IN DEPRESSED ADULTS AND ADOLESCENTS BEING TREATED WITH ANTIDEPRESSANTS

 

Anderson HD, Libby AM, Pace WD, West DR, Valuck RJ
University of Colorado, Denver, Aurora, CO, USA

PMH7

LIKELIHOOD OF POTENTIAL DRUG-DRUG INTERACTIONS AMONG PERSONS INITIATING THERAPY WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS: EFFECT OF INITIAL SSRI AND OTHER FACTORS

 

Valuck RJ1, Libby AM1, Anderson HD1, Erder M2, Milea D3, Doshi JA4, Collins C5, Preskorn S6
1University of Colorado, Denver, Aurora, CO, USA, 2Shire Pharmaceuticals, Wayne, PA, USA, 3Lundbeck SAS, Issy-les-Moulineaux, France, 4University of Pennsylvania, Philadelphia, PA, USA, 5University of Washington, Seattle, WA, USA, 6Clinical Research Institute, Wichita, KS, USA

PMH8

EFFECT OF VARIOUS ANTIDEPRESSANT GROUPS ON BONE MINERAL DENSITY (BMD)

 

Kurmanji JM1, Syed Sulaiman SA1, Chandrasekaran PK2, Kah LK3
1Universiti Sains Malaysia (USM), Penang, Malaysia, 2Penang Adventist Hospital, Penang, Malaysia, 3Penang General Hospital, Penang, Malaysia

PMH9

RISK OF DEATH IN DUAL ELIGIBLE NURSING HOME RESIDENTS USING ANTIPSYCHOTIC AGENTS

 

Aparasu RR, Mehta S, Chen H
University of Houston, Houston, TX, USA

PMH10

THE INFLUENCE OF COMORBID ANXIETY ON MEDICATION USE AND SERVICE UTILIZATION AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER: RESULTS FROM A RETROSPECTIVE CLAIMS DATABASE

 

Wu CH, Farley J
University of North Carolina, Chapel Hill, NC, USA

PMH11

PERFORMANCE OF RISK ADJUSTMENT SCALES IN PREDICTING RISK OF HOSPITALIZATION AMONG DEMENTIA PATIENTS: A MEPS STUDY

 

Bhowmik D, Mehta S, Chitnis A, Dwibedi N, Kamble P, Johnson ML
University of Houston, Houston, TX, USA

PMH12

THE PROFILE OF IMPAIRMENTS TO ATTENTION AND EPISODIC RECOGNITION MEMORY IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE

 

Wesnes K1, Lenderking WR2
1UBC, Goring-on-Thames, UK, 2UBC, Lexington, MA, USA

PMH13

COMPARATIVE EFFECTIVENESS STUDY OF RISPERIDONE LONG-ACTING INJECTABLE: THE USE OF DYNAMIC EXPOSURE METHODOLOGY FOR RISK SHARING AGREEMENT

 

Grimaldi-Bensouda L1, Rouillon F2, Abenhaim L3
1LA-SER Europe, Paris, France, 2Saint Anne Hospital, Paris, France, 3London School of Hygiene and Tropical Medicine, London, UK

PMH14

CLINICAL EFFECTIVENESS ANALYSIS OF NALTREXONE VERSUS ACAMPROSATE AND PLACEBO IN ALCOHOL DEPENDENT PATIENTS TREATED WITH PSYCHOTHERAPY

 

Jarosz J, Miernik K, Wachal M, Walczak J
Arcana Institute, Cracow, Poland

PMH15

IMPACT OF ADHERENCE TO FIRST THERAPY ON THE RISK OF ANTIDEPRESSANT SWITCHING

 

Jung SY, Shin S, Song H, Park J, Ahn J
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea

PMH16

CHARACTERISTICS OF PATIENTS IN COMMUNITY BEHAVIORAL HEALTH ORGANIZATIONS RECEIVING TWO INJECTABLE FORMS OF ATYPICAL ANTIPSYCHOTIC MEDICATIONS AS COMPARED WITH OTHER ANTIPSYCHOTICS

 

Mark T1, Panish J2, Mao L2, Montejano LB3, Dirani R4, Fastenau J2, Starr HL2
1Thomson Reuters, Washington, DC, USA, 2Johnson & Johnson, Titusville, NJ, USA, 3Thomson Reuters, Cambridge, MA, USA, 4Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA

PMH17

PREVALENCE OF ANTICHOLINERGIC DRUG PRESCRIBING IN ELDERLY OUTPATIENTS WITH DEMENTIA

 

Bhattacharya R, Chatterjee S, Aparasu R
University of Houston, Houston, TX, USA

PMH18

IMPACT OF COGNITIVE IMPAIRMENT ON FUNCTIONING, MEDICAL RESOURCE UTILIZATION, ADHERENCE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA

 

Lin FJ1, Bhor M2, Hass S2, Perry R3, Kay S3
1University of Illinois at Chicago, Chicago, IL, USA, 2Abbott Laboratories, Abbott Park, IL, USA, 3Adelphi Real World, Bollington, Cheshire, UK

Mental Health – Cost Studies

PMH19

THE BUDGET IMPACT ANALYSIS OF NALTREXONE IN THE TREATMENT OF ALCOHOL-DEPENDENT PATIENTS IN POLAND

 

Walczak J, Semeniuk A, Pacocha K, Nogas G
Arcana Institute, Cracow, Poland

PMH20

PSYCHOTROPIC MEDICATION USE AMONG CHILDREN WITH AUTISM SPECTRUM DISORDER: A COMPARISON BETWEEN MEDICAID AND COMMERCIAL INSURANCE

 

Wang L, Leslie D
Penn State College of Medicine, Hershey, PA, USA

PMH21

DIFFERENCES IN DAILY AVERAGE CONSUMPTION AND DAILY COSTS OF DESVENLAFAXINE, VENLAFAXINE XR, DULOXETINE, AND ESCITALOPRAM AMONG COMMERCIALLY INSURED PATIENTS

 

Whiteley J1, Makin C2, Klingman D2, Alvir J1, Harnett J1
1Pfizer, Inc., New York, NY, USA, 2IMS Health, Falls Church, VA, USA

PMH22

CLINICAL AND ECONOMIC CONSEQUENCES OF LONG-TERM USE OF BENZODIAZEPINES IN PATIENTS WITH GENERALIZED ANXIETY DISORDER

 

Berger A1, Edelsberg J1, Treglia M2, Alvir J3, Oster G1
1PAI, Brookline, MA, USA, 2Pfizer, Inc., New London, CT, USA, 3Pfizer, Inc., New York, NY, USA

PMH23

COMPARISON OF HEALTH CARE COSTS AND UTILIZATIONS BETWEEN PATIENTS WHO WERE TREATED WITH AND WITHOUT MEDICATION FOR OPIOID DEPENDENCY

 

Baser O, Wang L, Xie L
STATinMED Research, Ann Arbor, MI, USA

PMH24

COMPARISON OF HEALTH CARE COSTS AND UTILIZATIONS BETWEEN PATIENTS WHO WERE TREATED WITH PHARMACOLOGICAL AND NON-PHARMACOLOGICAL SUBSTANCE MEDICATIONS FOR ALCOHOL DEPENDENCY

 

Baser O, Wang L, Xie L
STATinMED Research, Ann Arbor, MI, USA

PMH25

CLINICAL OUTCOMES AND ECONOMIC COSTS OF SECOND-GENERATION ANTIPSYCHOTICS IN PATIENTS WITH CHRONIC SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDERS

 

Berger A1, Kushkuley S1, Sanders K2, Alvir J2, Oster G1
1PAI, Brookline, MA, USA, 2Pfizer, Inc., New York, NY, USA

PMH26

MEDICATION ADHERENCE AND HEALTH CARE COSTS AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH DULOXETINE

 

Zhao Y1, Cui Z1, Fang Y2, Faries D1
1Eli Lilly and Company, Indianapolis, IN, USA, 2inVentiv Clinical Solutions, Indianapolis, IN, USA

PMH27

IDENTIFICATION AND COST OF TREATMENT-RESISTANT DEPRESSION USING A CLAIMS SIGNATURE

 

Bates JA1, Cooke CE2, Hahn NM3, Lee HY4, Forbes RA5, Jing Y1
1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2PosiHealth, Inc., Ellicott City, MD, USA, 3University of Maryland School of Pharmacy, Baltimore, MD, USA, 4CareFirst BlueCross BlueShield, Baltimore, MD, USA, 5Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA

PMH28

REAL-WORLD HEALTH CARE UTILIZATION AND COSTS IN NEWLY DIAGNOSED DEPRESSION PATIENTS BETWEEN 2006 AND 2008

 

Schneider G1, Roy A2, Busner J3, Crean S1, Lanes S1, Dabbous OH2
1United BioSource Corporation, Lexington, MA, USA, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, 3United BioSource Corporation, Wayne, PA, USA

PMH29

ESTIMATION OF DIRECT COSTS OF TREATING SCHIZOPHRENIA FOR COMMUNITY-DWELLING UNITED STATES RESIDENTS

 

Desai P, Lawson K, Barner JC, Rascati KL
University of Texas at Austin, Austin, TX, USA

PMH30

INDIRECT COSTS (IC) OF ADULT WOMEN WITH ANXIETY DISORDERS (AD) IN THE UNITED STATES IN 2006 FROM THE MEDICAL EXPENDITURES PANEL SURVEY (MEPS)

 

Kavati A, Rappaport H
University of Louisiana at Monroe, Monroe, LA, USA

PMH31

TRAJECTORY ANALYSIS OF HEALTH CARE COSTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH HIGH DOSES OF DULOXETINE

 

Cui Z, Faries D, Zhao Y, Niu L, Novick D, Liu X
Eli Lilly and Company, Indianapolis, IN, USA

PMH32

COMPARISON OF REAL-WORLD HEALTH CARE COSTS AFTER THE INITIATION OF SECOND-LINE DULOXETINE OR GENERIC SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN PATIENTS WITH MAJOR DEPRESSIIVE DISORDER

 

Swindle R1, Ivanova JI2, Birnbaum HG3, Cummings AK3, Kantor E3, Schiller M2, Clark T1, Reed C4
1Eli Lilly and Company, Indianapolis, IN, USA, 2Analysis Group, Inc., New York, NY, USA, 3Analysis Group, Inc., Boston, MA, USA, 4Lilly UK, Windlesham, Surrey, UK

PMH33

THE EFFECTIVENESS OF BUPRENORPHINE-MEDICATION ASSISTED TREATMENT AMONG AETNA'S OPIOID DEPENDENT MEMBERS: AN ANALYSIS OF HEALTH CARE COSTS AND SERVICE UTILIZATION

 

Tkacz J1, Un H2, Leader Jr. D2, Ruetsch C1
1Health Analytics, LLC, Columbia, MD, USA, 2Aetna Behavioral Health, Blue Bell, PA, USA

PMH34

MEASURING THE IMPACT OF PERSISTENCE WITH PSYCHOTROPIC DRUG THERAPY ON TREATMENT COSTS FOR PATIENTS WITH SCHIZOPHRENIA

 

Zolfaghari S, McCombs J
USC School of Pharmacy, Los Angeles, CA, USA

PMH35

COMPARISONS OF MENTAL HEALTH-RELATED MEDICAL CARE UTILIZATION AND COSTS FOLLOWING THE INITIATION OF ORAL VERSUS LONG-ACTING INJECTABLE RISPERIDONE IN PATIENTS WITH SCHIZOPHRENIA

 

Park H, Kim DN, Rascati KL
University of Texas at Austin, Austin, TX, USA

PMH36

FACTORS ASSOCIATED WITH HEALTHCARE COSTS IN A POPULATION OF COMMERCIALLY INSURED CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER AND PSYCHIATRIC COMORBIDITIES

 

Slabaugh SL1, Durkin MB1, Montejano LB2
1Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2Thomson Reuters, Cambridge, MA, USA

PMH37

THE COST-EFFECTIVENESS OF GUANFACINE EXTENDED RELEASE (GXR) VERSUS ATOMOXETINE (ATX) FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS

 

Erder M1, Chen K2, Wu EQ2, Hodgkins P1, Sikirica V1
1Shire Pharmaceuticals, Wayne, PA, USA, 2Analysis Group, Inc., Boston, MA, USA

PMH38

ECONOMIC IMPLICATIONS OF THE EFFECT OF LURASIDONE VERSUS OTHER SELECTED ATYPICAL ANTIPSYCHOTICS ON CARDIOMETABOLIC PARAMETERS IN PATIENTS WITH SCHIZOPHRENIA

 

Guo S1, Hernandez L1, Green J1, Sarocco P2
1United BioSource Corporation, Lexington, MA, USA, 2Sunovion Pharmaceuticals Inc., Marlborough, MA, USA

PMH39

COST-EFFECTIVENESS OF ANTIDEPRESSANT THERAPIES IN KOREA

 

Shin S, Jung SY, Song H, Park J, Ahn J
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea

PMH40

COST-EFFECTIVENESS AND BUDGET IMPACT OF ADJUNCT QUETIAPINE FUMARATE EXTENDED-RELEASE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER WITH AN INADEQUATE RESPONSE TO PREVIOUS THERAPY

 

Svedsater H1, Locklear J2, Johal S3, Stillman IO4
1AstraZeneca, Mölndal, Sweden, 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 3RTI Health Solutions, Sheffield, UK, 4United BioSource Corporation, Lexington, MA, USA

PMH41

ECONOMIC EVALUATION OF DESVENLAFAXINE IN THE ACUTE MANAGEMENT OF INPATIENTS WITH MAJOR DEPRESSIVE DISORDER FROM A BRAZILIAN PUBLIC HOSPITAL PERSPECTIVE

 

Scaccabarozzi L1, Takemoto ML2, Fernandes RA2, Santos PML2, Tolentino ACM2
1Pfizer Pharmaceuticals Brazil, São Paulo, Brazil, 2ANOVA - Knowledge Translation, Rio de Janeiro, Brazil

PMH42

ECONOMIC EVALUATION OF DESVENLAFAXINE IN THE ACUTE MANAGEMENT OF ASSOCIATED MAJOR DEPRESSIVE DISORDER IN MEDICALLY ILL INPATIENTS FROM A BRAZILIAN PUBLIC GENERAL HOSPITAL PERSPECTIVE

 

Scaccabarozzi L1, Takemoto ML2, Fernandes RA2, Santos PML2, Tolentino ACM2
1Pfizer Pharmaceuticals Brazil, São Paulo, Brazil, 2ANOVA - Knowledge Translation, Rio de Janeiro, Brazil

PMH43

ECONOMIC IMPACT OF CYP450 PHARMACOGENETIC TESTING ON DEPRESSION TREATMENT

 

Syeda SS, Wu WK
St. John's University, Jamaica, NY, USA

PMH44

PHYSICAL AND MENTAL HEALTH AS IMPORTANT INPUTS INTO WAGE FUNCTION

 

Ghushchyan VH, Campbell JD, Libby AM
University of Colorado, Denver, Aurora, CO, USA

Mental Health – Patient-Reported Outcomes & Preference-Based Studies

PMH45

MEASURES OF MEDICATION ADHERENCE IN ORAL VERSUS LONG-ACTING RISPERIDONE IN TEXAS MEDICAID PATIENTS WITH SCHIZOPHRENIA

 

Kim DN, Park H, Rascati KL

University of Texas at Austin, Austin, TX, USA

PMH46

THE EFFECT OF ANTIPSYCHOTIC ADHERENCE ON ADHERENCE TO DIABETES, HYPERLIPIDEMIA, AND HYPERTENSION MEDICATIONS AND ASSOCIATED HEALTH SERVICE UTILIZATION

 

Farley J1, Hansen R2, Yu-Isenberg K3, Maciejewski M4
1University of North Carolina, Chapel Hill, NC, USA, 2Auburn University, Auburn, AL, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Duke University Medical Center, Durham, NC, USA

PMH47

THE RELATIONSHIP BETWEEN BUPRENORPHINE-MEDICATION ASSISTED TREATMENT ADHERENCE AND HEALTH CARE COSTS AND SERVICE UTILIZATION: AN ANALYSIS OF AETNA'S OPIOID DEPENDENT MEMBERS

 

Tkacz J1, Un H2, Leader Jr D2, Ruetsch C1
1Health Analytics, LLC, Columbia, MD, USA, 2Aetna Behavioral Health, Blue Bell, PA, USA

PMH48

PATIENT BELIEFS AND MEDICATION ADHERENCE IN BIPOLAR DISORDER: A NEED TO IMPROVE COUNSELING

 

Todd AM, Zuckerman IH
University of Maryland School of Pharmacy, Baltimore, MD, USA

PMH49

CAN THE ILLNESS PERCEPTION QUESTIONNAIRE BE USED TO ASSESS MENTAL HEALTH PRACTITIONERS' PERSPECTIVES ON PATIENTS WITH SCHIZOPHRENIA?

 

Fleming M, Martin CR
University of the West of Scotland, Ayr, UK

PMH50

A TIME-TRADE-OFF STUDY OF HEALTH-RELATED QUALITY OF LIFE ADVANTAGE OF LONG-ACTING INJECTABLE ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA

 

Osborne RH1, Dalton A2, Hertel J3, Schrover R4, Kingsford Smith D5
1Deakin University, Melbourne, Victoria, Australia, 2The University of Melbourne, Melbourne, Victoria, Australia, 3Janssen-Cilag Pty Ltd, North Ryde, NSW , Australia, 4Janssen-Cilag Pty Ltd & Decisionanalytics Pty Ltd, Sydney, NSW, Australia, 5Janssen-Cilag Pty Ltd, Sydney, NSW, Australia

PMH51

BASELINE RESULTS FROM BEAT THE BLUES

 

Pizzi LT1, Jutkowitz E1, Gitlin L1, Suh DC2, Dennis M1
1Thomas Jefferson University, Philadelphia, PA, USA, 2School of Pharmacy, Rutgers University, Piscataway, NJ, USA

PMH52

PATIENT AND PHYSICIAN PREFERENCES AND SATISFACTION WITH ORAL AND LONG-ACTING INJECTABLE LONG-TERM ANTIPSYCHOTIC TREATMENT FOR PSHCHOTIC DISORDERS

 

Prûtz C1, Andersson-Ljungberg G2, Hintikka J3, Opjordsmoen S4, Nielsen J5, Hansson F6
1Janssen Cilag AB, Sollentuna, Sweden, 2University Hospital of Gothenburg, Göteborg, Sweden, 3Kuopio University Hospital of Psychiatry, Kuopio, Finland, 4Oslo University Hospital, Oslo, Norway, 5Aalborg University Hospital, Aalborg, Denmark, 6Commitum, Lund, Sweden

PMH53

ASSESSING THE IMPACT OF MAJOR DEPRESSIVE DISORDER (MDD) ON FAMILY FUNCTIONING: DEVELOPMENT OF THE DEPRESSION AND FAMILY FUNCTIONING SCALE

 

Lançon C1, DiBenedetti DB2, Lewis S2, Davis K2, Danchenko N3, François C3
1Hopital Sainte-Marguerite CHU, Marseille , France, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Lundbeck SAS, Issy-les-Moulineaux, France

PMH54

CAREGIVER BURDEN IN SCHIZOPHRENIA - A SYSTEMATIC REVIEW

 

Shah D1, Kamal KM2
1Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA, 2Duquesne University, Pittsburgh, PA, USA

PMH55

THE BURDEN OF DIAGNOSED DEPRESSION AND SLEEP DIFFICULTIES ON QUALITY OF LIFE, WORK PRODUCTIVITY, AND RESOURCE USE

 

Gupta S1, Goren A2, Gabriel S3, Kim E3, Dupclay L3
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PMH56

COMPARISON OF DIFFERENT COMORBIDITY MEASURES FOR PREDICTING PHYSICAL AND MENTAL HEALTH IN DEMENTIA

 

Chitnis A, Bhowmik D, Dwibedi N, Mehta S, Kamble P, Johnson ML
University of Houston, Houston, TX, USA

PMH57

ASSOCIATION BETWEEN WORK PRODUCTIVITY AND SEVERITY OF DEPRESSION AMONG FULL-TIME EMPLOYEES AS MEASURED BY THE WPAI & HPQ

 

Jain G1, Roy A2, Harikrishnan V2, Yu S2, Dabbous OH2
1Xcenda, LLC., Palm Harbor, FL, USA, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA

Mental Health – Health Care Use & Policy Studies

PMH58

NEW DISEASE MANAGEMENT PROGRAM FOR OPIOID DEPENDENT PATIENTS DECREASES DRUG USE AND INCREASES 12 STEP MEETING ATTENDANCE: ONE YEAR RESULTS OF A RANDOMIZED CLINICAL TRIAL

 

Tkacz J, Ruetsch C
Health Analytics, LLC, Columbia, MD, USA

PMH59

DIFFERENCES IN BASELINE PROBLEM SEVERITY BETWEEN PRESCRIPTION AND STREET OPIOID ABUSERS AMELIORATED AFTER PARTICIPATION IN DISEASE MANAGEMENT PROGRAM: RESULTS AT ONE YEAR

 

Tkacz J, Ruetsch C
Health Analytics, LLC, Columbia, MD, USA

PMH60

BIPOLAR DISORDER RESULTS IN SIGNIFICANT BURDEN ON CAREGIVERS: ANALYSIS OF DATA FROM A LARGE MULTINATIONAL LONGITUDINAL STUDY (WAVE-BD)

 

Vieta E1, Figueira ML2, Bellivier F3, Souery D4, Blasco-Colmenares E5, Langosch JM6, Medina E7
1Bipolar Disorders Programme, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain, 2Hospital Santa Maria, Faculty of Medicine, University of Lisbon, Lisboa, Portugal, 3Hôpital Henri Mondor, Créteil, France, 4Centre Européen de Psychologie Médicale, Psy-Pluriel, Brussels, Belgium, 5Johns Hopkins Bloomsberg School of Public Health, Baltimore, MD, USA, 6Bethanien Hospital for Psychiatry, Psychosomatics, and Psychotherapy, Greifswald, Germany, 7Medical Department, AstraZeneca Pharmaceuticals, Madrid, Spain

PMH61

NATIONAL ESTIMATES AND CHARACTERISTICS OF AMBULATORY CARE VISITS FOR DEMENTIA CARE IN THE UNITED STATES, 1998–2007

 

Sankaranarayanan J1, Chen Y2, Murman DL1
1University of Nebraska Medical Center, Omaha, NE, USA, 2Covance Market Access Services, Inc., Gaithersburg, MD, USA

PMH62

TREND IN UTILIZATION OF AND SPENDING ON BENZODIAZEPINES IN THE UNITED STATES MEDICAID PROGRAM: 1991-2009

 

Bian B, Gorevski E, Guo JJ, Boone J, Kelton CM
University of Cincinnati, Cincinnati, OH, USA

PMH63

RISK-BENEFIT ANALYSIS OF DEPRESSION TREATMENT FOR CHILDREN AND YOUNG ADULTS

 

Soeteman DI, Miller M, Kim J
Harvard School of Public Health, Boston, MA, USA

PMH64

COMPARISON OF THE RISPERIDONE EQUIVALENT DOSES FOR THE 9 MOST FREQUENT TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN PATIENTS DIAGNOSED WITH SCHIZOPHRENIA BASED ON PRODUCT LABELS WITH ACTUAL DOSAGES PRESCRIBED IN A LARGE NATIONAL DATABASE

 

Parente AK, Wang RH, Jones BT
MedAssurant, Bowie, MD, USA

PMH65

EFFECT OF PRESCRIPTION MONITORING PROGRAMS (PMP'S) ON OPIOID OVERDOSE ADMISSION

 

Painter JT
University of Kentucky, Lexington, KY, USA

PMH66

MULTIMORBIDITY AND DEPRESSION TREATMENT

 

Vyas A, Sambamoorthi U
West Virginia University, Morgantown, WV, USA

PMH67

CO-PRESCRIBING CHOLINESTERASE INHIBITORS WITH ANTICHOLINERGIC URINARY INCONTINENCE MEDICATIONS

 

Stephens M1, Heaton P2
1University of Cincinnati, James L. Winkle College of Pharmacy, Cincinnati, OH, USA, 2University of Cincinnati, Cincinnati, OH, USA

PMH68

FDA REGULATIONS AND ANTIDEPRESSANT UTILIZATION

 

Campbell CJ, Pickard AS, Schumock GT
University of Illinois at Chicago, Chicago, IL, USA

PMH69

HEALTH CARE RESOURCE UTILIZATION AMONG PATIENTS WITH BIPOLAR DISORDER: RETROSPECTIVE DATA FROM A LARGE MULTINATIONAL LONGITUDINAL STUDY (WAVE-BD)

 

Vieta E1, Figueira ML2, Bellivier F3, Souery D4, Blasco-Colmenares E5, Langosch JM6, Medina E7
1Bipolar Disorders Programme, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain, 2Hospital Santa Maria, Faculty of Medicine, University of Lisbon, Lisboa, Portugal, 3Hôpital Henri Mondor, Créteil, France, 4Centre Européen de Psychologie Médicale, Psy-Pluriel, Brussels, Belgium, 5Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 6Bethanien Hospital for Psychiatry, Psychosomatics, and Psychotherapy, Greifswald, Germany, 7AstraZeneca Pharmaceuticals LP, Madrid, Spain

PMH70

WHAT DROVE THE DRAMATIC SLOWDOWN IN PSYCHIATRIC DRUG SPENDING GROWTH IN THE UNITED STATES

 

Mark T
Thomson Reuters, Washington, DC, USA

PMH71

HEALTH CARE RESOURCE UTILIZATION (HRU) AND DIRECT MEDICAL EXPENDITURES (DME) FOR ADULT WOMEN WITH ANXIETY DISORDERS (AD) IN THE UNITED STATES IN 2006 USING MEDICAL EXPENDITURES PANEL SURVEY (MEPS)

 

Kavati A, Rappaport H
University of Louisiana at Monroe, Monroe, LA, USA

PMH72

ANTIDEPRESSANT PERSISTENCE AND ASSOCIATED HEALTH CARE EXPENDITURES IN CHILDREN WITH DEPRESSION

 

Karkare S1, Aparasu RR2, Chen H2, Rajan SS2
1Center for Medical Technology and Policy, Baltimore, MD, USA, 2University of Houston, Houston, TX, USA

PMH73

RETROSPECTIVE ANALYSIS OF THE IMPACT OF PERSISTENCE ON HEALTH CARE CHARGES AMONG OPIOID-DEPENDENT PATIENTS TREATED WITH BUPRENORPHINE/NALOXONE USING AN INSURANCE DATABASE IN THE UNITED STATES

 

Zah V1, Aballea S2, Guelfucci F3, Clay E3, Baxter T4
1ISPOR Serbia, Beograd, Serbia and Montenegro, 2Creativ Ceutical, Paris, Ile de France, France, 3Creativ Research, Paris, France, 4Reckitt Benckiser Pharmaceuticals Inc, Richmond, VA, USA

PMH74

UTILIZATION, PRICE AND SPENDING TRENDS FOR SEROTONIN–NOREPINEPHRINE REUPTAKE INHIBITORS IN THE UNITED STATES MEDICAID PROGRAM: 1991-2009

 

Isla A, Guo JJ, Lin AC, Kelton CM, Heaton PC
University of Cincinnati, Cincinnati, OH, USA

PMH75

PSYCHIATRIC MORBIDITY AND BURNOUT AMONG HOSPITAL PHYSICIANS AND NURSES: ASSOCIATION WITH PERCEIVED JOB-RELATED FACTORS

 

Tabolli S, di Pietro C, Renzi C
IDI IRCCS, Rome, Italy

PMH76

PHARMACIST AND PHARMACY STAFF KNOWLEDGE AND ATTITUDES TOWARDS SUICIDE AND SUICIDE PREVENTION AFTER A NATIONAL VA TRAINING PROGRAM

 

Lavigne JE, King DA, Lu N, Knox KL, Kemp JE
U.S. Department of Veterans Health Affairs, Canandaigua, NY, USA

PMH77

UTILIZATION PATTERN OF PSYCHOTHERAPY AS AN ADJUNCT TO PHARMACOTHERAPY AMONG AMBULATORY BIPOLAR DISORDER PATIENTS

 

Mehta S, Bhattacharya R, Aparasu RR
University of Houston, Houston, TX, USA

PMH78

PERSISTENCE OF STIMULANT TREATMENT IN CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER

 

Palli SR1, Aparasu RR2, Chen H2, Sherer JT2
1HealthCore, Inc., Wilmington, DE, USA, 2University of Houston, Houston, TX, USA

PMH79

PSYCHOTROPIC POLYPHARMACY IN CHILDREN AND ADOLESCENTS WITH ATTENTION – DEFICIT / HYPERACTIVITY DISORDER

 

Palli SR1, Aparasu RR2, Chen H2, Sherer JT2
1HealthCore, Inc., Wilmington, DE, USA, 2University of Houston, Houston, TX, USA

PMH80

UTILIZATION PATTERN AND TREATMENT ADHERENCE WITH MOOD STABILIZERS AND ATYPICAL ANTIPSYCHOTICS AMONG PEDIATRIC PATIENTS WITH BIPOLAR DISORDER: A RETROSPECTIVE CLAIMS-BASED STUDY

 

Mehta S, Patel A, Chen H
University of Houston, Houston, TX, USA

Mental Health – Research on Methods

PMH81

RELATIONSHIP BETWEEN ADHERENCE TO ANTIDEPRESSANT TREATMENTS AND DEPRESSIVE RELAPSE

 

Jung SY, Shin S, Song H, Park J, Ahn J
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea

PMH82

VALIDATION AND PSYCHOMETRIC EVALUATION OF A BRIEF COMBINED ASSESSMENT OF DEPRESSION AND ANXIETY

 

McCarrier KP1, Bushnell DM1, Martin ML2, Paczkowski R3, Nelson DR3, Buesching D3
1Health Research Associates, Inc., Mountlake Terrace, WA, USA, 2Health Research Associates, Inc., Seattle, WA, USA, 3Eli Lilly and Company, Indianapolis, IN, USA

PMH83

ESTIMATING SAMPLE SIZE FOR PSYCHOMETRIC STUDIES USING CONFIRMATORY FACTOR ANALYSIS

 

Cole JC, Cheng R
Covance Market Access Services, Inc., San Diego, CA, USA

PMH84

PERFORMANCE OF TWO INSTRUMENTAL VARIABLES TO EXAMINE THE RISK OF DEATH IN DUAL ELIGIBLE ELDERLY NURSING HOME RESIDENTS USING ANTIPSYCHOTIC AGENTS

 

Aparasu RR, Mehta S, Chen H
University of Houston, Houston, TX, USA

PMH85

A SCHIZOPHRENIA OR BIPOLAR TYPE I DISORDER REGISTRY: LESSONS LEARNED FROM CONDUCTING A REGISTRY STUDY WITH SAFETY NET PROVIDERS

 

Panish J1, Dirani R2, Mark T3, Montejano LB4, Starr HL1, Mao L1
1Johnson & Johnson, Titusville, NJ, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3Thomson Reuters, Washington, DC, USA, 4Thomson Reuters, Cambridge, MA, USA

POSTER PRESENTATIONS SESSION III
SET-UP: Wednesday, May 25, 2011 - 7:30AM – 8:00AM
POSTER DISPLAY HOURS: Wednesday, May 25, 2011 - 8:00AM – 3:00PM
POSTER AUTHOR DISCUSSION HOUR: Wednesday, May 25, 2011 - 11:45AM - 12:45PM
DISMANTLE: Wednesday, May 25, 2011 - 3:00PM – 3:30PM

Neurological Disorders – Clinical Outcomes Studies

PND1

PRESCRIBING PATTERNS OF DRUGS HAVING ANTICHOLINERGIC ACTIVITY IN PATIENTS WITH ALZHEIMER'S DISEASE

 

Gala SD, Gupte KP, Wu WK
St. John's University, Jamaica, NY, USA

PND2

AN EPIDEMOLOGIC EVALUATION OF COMORBID CONDITIONS IN PATIENTS WITH MULTIPLE SCLEROSIS

 

Livingston TP1, Foulds P2, Asselin R2
1Biogen Idec, Las Vegas, NV, USA, 2Biogen Idec, Wellesley, MA, USA

PND3

THE NATURE AND PREVALENCE OF COMORBID ILLNESS AMONG INDIVIDUALS WITH MULTIPLE SCLEROSIS

 

Stewart M1, Phillips A2, Edwards N3, Gupta S4, Goren A5
1Pfizer, Inc., New London, CT, USA, 2EMD Serono, Inc., Rockland, MA, USA, 3Health Services Consulting Corporation, Boxborough, MA, USA, 4Kantar Health, Princeton, NJ, USA, 5Kantar Health, New York, NY, USA

PND4

DIAGNOSIS OF SHIFT WORK DISORDER AND THE IMPACT OF EXCESSIVE SLEEPINESS: RESULTS FROM SHIFT WORKERS, PATIENTS WITH SHIFT WORK DISORDER, AND HEALTH CARE PROFESSIONALS PARTICIPATING IN AN INTERNET SURVEY

 

Anderson C1, Sylvester L2, Paik S2
1Cephalon, Inc., Frazer, PA, USA, 2IPSOS, Norwalk, CT, USA

PND5

ASSESSMENT OF PARKINSON'S DISEAES PROGRESSION RATES BY STAGE OF DISEASE

 

Johnson SJ1, Kaltenboeck A1, Diener M1, Tarrants M2, Birnbaum H3
1Analysis Group, Inc., New York, NY, USA, 2Teva Neuroscience, Kansas City, MO, USA, 3Analysis Group, Inc., Boston, MA, USA

PND6

THE IMPACT OF SPECIALTY CARE PROGRAMS ON RELAPSES OF MULTIPLE SCLEROSIS USING ADMINISTRATIVE DATA

 

Tang J1, Levin MC1, Bailey JE1, Faris RJ2, Hong SH1, Chang CF3, Wang J1
1University of Tennessee Health Science Center, Memphis, TN, USA, 2Accredo Health, Memphis, TN, USA, 3The University of Memphis, Memphis, TN, USA

PND7

PREVALENCE OF DRUG-TREATED MULTIPLE SCLEROSIS WITHIN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM: COMPARATIVE ANALYSIS WITH PUBLISHED PREVALENCE RATES

 

Takemoto ML, Takemoto MMS, Fernandes RA, Duarte GGF, Tolentino ACM, Santos PML, Moretti AIP
ANOVA - Knowledge Translation, Rio de Janeiro, Brazil

PND8

INCIDENCE RATES OF SUBARACHNOID HEMORRHAGE IN PATIENTS WITH UNRUPTURED ANEURYSM IN SOUTH KOREA FROM 2006-2009

 

Lee EJ, Kwon JW, Lee HJ, Hyun MK, Hwang JS, Kim J, Choi J, Lee NR
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea

PND9

FACTORS AFFECTING FUNCTIONAL DEPENDENCE IN ALZHEIMER PATIENTS RESIDING IN NURSING HOMES IN THE UNITED STATES - USING NATIONAL NURSING HOME SURVEY (NNHS-2004)

 

Kale H, Nair R
St. John's University, Queens, NY, USA

Neurological Disorders – Cost Studies

PND10

BUDGET IMPACT ANALYSIS OF EVEROLIMUS FOR THE TREATMENT OF GROWING SUBEPENDYMAL GIANT CELL ASTROCYTOMA SECONDARY TO TUBEROUS SCLEROSIS COMPLEX

 

Stillman IO1, Whalen JD1, Sun P2, Liu Z3
1United BioSource Corporation, Lexington, MA, USA, 2Kailo Research Group, Fishers, IN, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PND11

THE ECONOMIC BURDEN OF OSA IN EACH OF THE METABOLIC SYNDROME COMPONENTS LEVELS

 

Greenberg-Dotan S1, Yan X2, Scharf SM2, Shaya FT3
1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2University of Maryland, Baltimore, MD, USA, 3University of Maryland School of Pharmacy, Baltimore, MD, USA

PND12

LOWER DAILY AVERAGE CONSUMPTION AND GREATER PRESCRIPTION COST SAVINGS OF ARMODAFINIL COMPARED WITH MODAFINIL: A 12-MONTH RETROSPECTIVE DATABASE ANALYSIS

 

Carlton R1, Regan TS1, Rice G2
1Xcenda, LLC., Palm Harbor, FL, USA, 2ITSRx, Houston, TX, USA

PND13

BURDEN OF ILLNESS IN THE UNITED STATES FOR PEDIATRIC EPILEPSY PATIENTS WITH PARTIAL ONSET SEIZURES RECEIVING ANTI-EPILEPTIC DRUGS

 

Copher R1, Angalakuditi M2
1i3 Innovus, Eden Prairie, MN, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA

PND14

BURDEN OF ILLNESS IN THE UNITED STATES FOR ADULT EPILEPSY PATIENTS WITH PARTIAL ONSET SEIZURES RECEIVING ANTI-EPILEPTIC DRUGS

 

Copher R1, Angalakuditi M2
1i3 Innovus, Eden Prairie, MN, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA

PND15

THE INCREMENTAL COST OF ALZHEIMER'S DISEASE IN THE CALIFORNIA MEDICAID PROGRAM (MEDI-CAL)

 

McCombs J1, Chu K2, Mucha L3
1USC School of Pharmacy, Los Angeles, CA, USA, 2University of Southern California, Los Angeles, CA, USA, 3Pfizer, Inc., Collegeville, PA, USA

PND16

CHARACTERIZING DIRECT COSTS ASSOCIATED WITH HEMOPHILIA A: A RESOURCE-BASED COST ANALYSIS

 

Zhou ZY1, Ullman M2, Koerper M3, Baker J4, Smith C5, Poon JL1, Lou M1, Johnson K1
1USC School of Pharmacy, Los Angeles, CA, USA, 2University of Texas Health Science Center at Houston, Houston, TX, USA, 3UCSF HTC, San Francisco, CA, USA, 4UCLA Division of Hematology/Oncology, Los Angeles, CA, USA, 5University of Colorado, Denver Hemophilia and Thrombosis Center, Aurora, CO, USA

PND17

IMPACT OF WALKING AND MOBILITY PROBLEMS ON REQUIREMENT FOR HEALTHCARE AMONG MULTIPLE SCLEROSIS PATIENTS

 

Rajagopalan K1, Pike J2, Jones E2, Anderson P2
1Biogen Idec, Wellesley, MA, USA, 2Adelphi Real World, Macclesfield, Cheshire, UK

PND18

BURDEN OF WALKING AND MOBILITY PROBLEMS IN MS: ANALYSIS OF CAREGIVER AND INDIRECT COSTS

 

Piercy J1, Rajagopalan K2, Jones E1, Pike J1
1Adelphi Real World, Macclesfield, Cheshire, UK, 2Biogen Idec, Wellesley, MA, USA

PND19

HUMANISTIC AND ECONOMIC BURDEN IN TUBEROUS SCLEROSIS COMPLEX WITH NEUROLOGICAL MANIFESTATIONS: SYSTEMATIC REVIEW

 

Hallett L1, Foster T1, Valentim J2, Blieden M1, Liu Z3
1United BioSource Corporation, Lexington, MA, USA, 2Novartis Pharmaceuticals, Sao Paulo, Brazil, 3Novartis Pharmaceuticals, East Hanover, NJ, USA

PND20

HEALTHCARE UTILIZATION AND COSTS AMONG AD PATIENTS WITH AND WITHOUT DYSPHAGIA

 

Gabriel S, Tian H, Kim E, Kahler KH
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PND21

ESTIMATED COSTS OF FINGOLIMOD MONITORING FOR INDIVIDUALS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS

 

Trautman H1, Clark J2, Huleatt H1
1Aventine Consulting, Marblehead, MA, USA, 2Aventine Consulting, University Place, WA, USA

PND22

QUANTIFYING COST OUTCOMES DIFFERENTIATED BY GENDER AND AGE IN THE TREATMENT OF MIGRAINE HEADACHE USING STEP AND STRATIFIED CARE

 

Furiak N, Bansal M
Medical Decision Modeling Inc., Indianapolis, IN, USA

PND23

ECONOMIC EVALUATION OF DEXMEDETOMIDINE FOR SEDATION IN THE INTENSIVE CARE UNIT

 

Lachaine J, Beauchemin C
University of Montreal, Montreal, QC, Canada

PND24

QUALITY OF LIFE USING TREATMENTS FOR PARKINSON'S DISEASE: AN ECONOMIC COMPARISON BETWEEN ROPINIROLE AND LEVODOPA/CARBIDOPA

 

Patil DS, Shah AJ, Sansgiry S
University of Houston, Houston, TX, USA

PND25

ECONOMIC TRENDS ASSOCIATED WITH NATALIZUMAB THERAPY IN A COMMERCIALY MANAGED MULTIPLE SCLEROSIS POPULATION

 

Pill M, Gilkin B
Gemini Healthcare, LLC, Westbrook, CT, USA

PND26

MEASURING THE IMPACT OF NATALIZUMAB THERAPY ON HEALTH CARE UTILIZATION IN A COMMERCIALY MANAGED MULTIPLE SCLEROSIS POPULATION

 

Pill M, Gilkin B
Gemini Healthcare, LLC, Westbrook, CT, USA

PND27

MEDICO-ECONOMIC EVALUATION OF LACOSAMIDE ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH REFRACTORY EPILEPSY IN THE UNITED STATES

 

Benhaddi H1, Helmers S2
1UCB Group, Brussels, Belgium, 2Emory University School of Medicine, Atlanta, GA, USA

Neurological Disorders – Patient-Reported Outcomes & Preference-Based Studies

PND28

THE RELATIONSHIP BETWEEN ALTERNATIVE MEDICATION POSESSION RATIO THRESHOLDS AND OUTCOMES: EVIDENCE FROM THE USE OF GLATIRAMER ACETATE

 

Oleen-Burkey M1, Castelli-Haley J1, Dor A2, Lage M3
1Teva Pharmaceuticals, Kansas City, MO, USA, 2George Washington University, Washington, DC, USA, 3HealthMetrics Outcomes Research, Groton, CT, USA

PND29

VALIDATION OF THE HUNTINGTON CLINICAL SELF-REPORTED INSTRUMENT (H-CSRI), A CLINIMETRIC PATIENT ASSESSED SCALE FOR PATIENTS WITH HUNTINGTON'S DISEASE

 

Clay E1, Dorey J2, Toumi M3, Tedroff J4, Squitieri F5, De Nicola N5, Verny C6
1Creativ Research, Paris, France, 2Creativ Ceutical, Paris, France, 3University of Lyon, Lyon, France, 4NEUROSEARCH, Ballerup, Denmark, 5Neurogenetics and Rare Disease Centre, Pozzi, Italy, 6Centre national de référence des maladies neurogénétiques, Angers, France

PND30

QUALITY OF LIFE AMONG PATIENTS SUFFERING FROM MIGRAINE: HEALTH UTILITY BY FREQUENCY OF HEADACHE DAYS

 

Gillard P1, Devine B2, Bloudek LM1, Liu L1, Varon SF1, Lipton RB3, Sullivan SD2
1Allergan, Inc., Irvine, CA, USA, 2University of Washington, Seattle, WA, USA, 3Albert Einstein College of Medicine, Bronx, NY, USA

PND31

HEADACHE DAY HEALTH STATES AND TRANSITION PROBABILITIES FOR PATIENTS WITH CHRONIC MIGRAINE WITH AND WITHOUT HEADACHE PROPHYLAXIS

 

Bloudek LM1, Hansen RN2, Liu L1, Batty AJ3, Varon SF1, Lipton RB4, Sullivan SD2
1Allergan, Inc., Irvine, CA, USA, 2University of Washington, Seattle, WA, USA, 3BresMed Health Solutions, Sheffield, UK, 4Albert Einstein College of Medicine, Bronx, NY, USA

PND32

HEALTH RESOURCE UTILIZATION AND COSTS FOR MIGRANEURS IN SCOTLAND

 

Bloudek LM1, Hansen RN2, Liu L1, Batty AJ3, Varon SF1, Lipton RB4, Sullivan SD2
1Allergan, Inc., Irvine, CA, USA, 2University of Washington, Seattle, WA, USA, 3BresMed Health Solutions, Sheffield, UK, 4Albert Einstein College of Medicine, Bronx, NY, USA

PND33

UTILIZING A PAPER STANDARD GAMBLE INSTRUMENT TO ASSESS HEALTH UTILITY IN PATIENTS WITH HEMOPHILIA B

 

Lou M1, Zhou ZY1, Gwadry-Sridhar F2, Poon JL1, Doctor J1, Koerper M3, Ullman M4, Johnson K1
1USC School of Pharmacy, Los Angeles, CA, USA, 2University of Western Ontario, London, ON, Canada, 3UCSF HTC, San Francisco, CA, USA, 4University of Texas Health Science Center at Houston, Houston, TX, USA

PND34

MAPPING THE INSOMNIA SEVERITY INDEX (ISI) TO THE EQ-5D UTILITIES

 

Gu NY1, Ji X1, Bell C2, Botteman M1
1Pharmerit North America, LLC, Bethesda, MD, USA, 2GlaxoSmithKline, Research Triangle Park, NC, USA

PND35

CREATION OF A WEB-BASED MULTIPLE SCLEROSIS PATIENT-REPORTED OUTCOMES RESEARCH PROGRAM

 

Deering K1, Agarwal SS2, Rajagopalan K2, Harshaw Q1, Shillington AC1
1EPI-Q, Inc., Oak Brook, IL, USA, 2Biogen Idec, Wellesley, MA, USA

PND36

INTERNAL LOCUS OF CONTROL AND TREATMENT SATISFACTION WITH NATALIZUMAB

 

Stephenson JJ1, Kern DM1, Agarwal SS2, Kamat SA1
1HealthCore, Inc., Wilmington, DE, USA, 2Biogen Idec, Wellesley, MA, USA

PND37

INVESTIGATION OF THE PSYCHOMETRIC PROPERTIES OF THE SHORT PARKINSON'S EVALUATION SCALE / SCALES FOR OUTCOMES IN PARKINSON'S DISEASE (SPES/SCOPA)

 

Buck PO1, Conner JB1, Castelli-Haley J1, Wilson RE2, Seeberger LC3
1Teva Neuroscience, Kansas City, MO, USA, 2Brentwood Neurology, Brentwood, TN, USA, 3Idaho Elks Rehabilitation Hospital, Nampa, ID, USA

PND38

THE HIDDEN TOLL OF CAREGIVER BURDEN IN MULTIPLE SCLEROSIS

 

Stewart M1, Phillips A2, Edwards N3, Gupta S4, Goren A5
1Pfizer, Inc., New London, CT, USA, 2EMD Serono, Inc., Rockland, MA, USA, 3Health Services Consulting Corporation, Boxborough, MA, USA, 4Kantar Health, Princeton, NJ, USA, 5Kantar Health, New York, NY, USA

PND39

MULTIPLE SCLEROSIS PATIENTS REPORT IMPROVEMENTS IN FATIGUE AND COGNITIVE FUNCTIONING AFTER ONE YEAR OF NATALIZUMAB TREATMENT

 

Stephenson JJ1, Agarwal SS2, Kern DM1, Kamat SA1
1HealthCore, Inc., Wilmington, DE, USA, 2Biogen Idec, Wellesley, MA, USA

PND40

ASSESSMENT OF PERCEIVED SEVERITY OF DISEASE AND SYMPTOMS, QUALITY OF LIFE, WORK PRODUCTIVITY, AND HEALTH CARE RESOURCE USE IN INDIVIDUALS WITH MULTIPLE SCLEROSIS

 

Phillips A1, Stewart M2, Edwards N3, Gupta S4, Goren A5
1EMD Serono, Inc., Rockland, MA, USA, 2Pfizer, Inc., New London, CT, USA, 3Health Services Consulting Corporation, Boxborough, MA, USA, 4Kantar Health, Princeton, NJ, USA, 5Kantar Health, New York, NY, USA

PND41

PARNETING STRESS IN CARING FOR CHILDREN DIAGNOSED WITH NEURO-DEVELOPMENTAL DISORDER

 

Almogbel YS, Goyal R, Sansgiry S
University of Houston, Houston, TX, USA

PND42

THE ASSOCIATION BETWEEN PARKINSON’S DISEASE QUESTIONNAIRE (PDQ) SCORES WITH CARER STRAIN AND QUALITY OF LIFE

 

Jenkinson C1, Peters M2, Fitzpatrick R2, Churchman D3
1University of Oxford, Health Services Research Unit, Oxford, Oxfordshire, UK, 2University of Oxford, Oxford, Oxfordshire, UK, 3Isis Innovation Ltd., Oxford, Oxfordshire, UK

PND43

THE PATIENTSLIKEME® EPILEPSY COMMUNITY: A UNIQUE INSIGHT INTO THE LIVES OF PATIENTS WITH EPILEPSY

 

de la Loge C1, Dimova S1, Massagli M2, Wicks P2
1UCB Pharma S.A., Brussels, Belgium, 2PatientsLikeMe, Cambridge, MA, USA

PND44

HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS WITH DYSPORT IN CERVICAL DYSTONIA

 

Coleman C1, Chang S1, Copley-Merriman C2, Masaquel C2, Hubble J1
1IPSEN US, Brisbane, CA, USA, 2RTI Health Solutions, Ann Arbor, MI, USA

PND45

ONE YEAR OF NATALIZUMAB TREATMENT IS ASSOCIATED WITH AN IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS

 

Stephenson JJ1, Agarwal SS2, Kern DM1, Kamat SA1
1HealthCore, Inc., Wilmington, DE, USA, 2Biogen Idec, Wellesley, MA, USA

PND46

THE IMPACT OF EPILEPSY ON ADULT AND PAEDIATRIC PATIENT'S LIVES: A CONCEPTUAL MODEL

 

Kerr C1, Nixon A1, Angalakuditi M2
1Oxford Outcomes Ltd., Oxford, Oxon, UK, 2Eisai, Inc., Woodcliff Lake, NJ, USA

PND47

THE HEMOPHILIA UTILIZATION GROUP STUDY (HUGS-VB): HEALTH-RELATED QUALITY OF LIFE IN HEMOPHILIA B

 

Poon JL1, Lou M1, Doctor J1, Zhou ZY1, Gwadry-Sridhar F2, Baker J3, Ullman M4, Koerper M5, Johnson K1
1USC School of Pharmacy, Los Angeles, CA, USA, 2University of Western Ontario, London, ON, Canada, 3UCLA Division of Hematology/Oncology, Los Angeles, CA, USA, 4University of Texas Health Science Center at Houston, Houston, TX, USA, 5UCSF HTC, San Francisco, CA, USA

PND48

MEASUREMENT CHARACTERISTICS OF THE SF-36 IN CHRONIC NEUROMUSCULAR DISORDER

 

Banks P1, Martin CR2, Petty R3
1University of the West of Scotland, Hamilton, UK, 2University of the West of Scotland, Ayr, UK, 3Southern General Hospital, Glasgow, UK

PND49

MEASUREMENT CHARACTERISTICS OF THE SF-36 IN PARKINSON'S DISEASE

 

Banks P1, Martin CR2
1University of the West of Scotland, Hamilton, UK, 2University of the West of Scotland, Ayr, UK

PND50

UNDERSTANDING HEALTH RELATED QUALITY OF LIFE CHANGES AND ISSUES RELATED TO DISEASE MODIFYING DRUGS AMONG MULTIPLE SCLEROSIS PATIENTS: A QUALITATIVE STUDY

 

Bhanegaonkar A1, Madhavan S1, Pawar GV1, Rajagopalan K2, Langlois J3
1West Virginia University, Morgantown, WV, USA, 2Biogen Idec, Wellesley, MA, USA, 3JKL Research Associates, Tampa , FL, USA

Neurological Disorders – Health Care Use & Policy Studies

PND51

THE EFFECT OF THE MEDICARE PART D COVERAGE GAP AND OUT-OF-POCKET BURDEN ON THE USE OF DISEASE MODIFYING DRUGS TO TREAT MULTIPLE SCLEROSIS

 

Banahan BFI1, Datar M1, Mendonca CM1, Shahpurwala Z1, Bentley JP1, Phillips AL2, Stewart M3
1University of Mississippi, University, MS, USA, 2EMD Serono, Inc., Rockland, MA, USA, 3Pfizer, Inc., New London, CT, USA

PND52

HEALTH CARE RESOURCE UTILIZATION BEFORE AND AFTER INITIATION OF ARMODAFINIL TREATMENT FOR WAKEFULNESS

 

Carlton R1, Regan TS1, Lunacsek O1, Dammerman R2
1Xcenda, LLC., Palm Harbor, FL, USA, 2Cephalon, Inc., Frazer, PA, USA

PND53

UNCONTROLLED EPILEPSY IN A MEDICAID POPULATION

 

Paradis PE1, Manjunath R2, Duh MS3, Lafeuille MH1, Mishagina N1, Parisé H1, Rovba L1, Lefebvre P1, Faught E4
1Groupe d'analyse, Ltee, Montréal, QC, Canada, 2GlaxoSmithKline, Research Triangle Park, NC, USA, 3Analysis Group, Inc., Boston, MA, USA, 4Emory University, Atlanta, GA, USA

PND54

RETROSPECTIVE DATABASE ANALYSIS OF FREQUENCY AND COSTS OF RELAPSES AMONG MULTIPLE SCLEROSIS PATIENTS

 

Boklage S, Preblick R, Yaldo A, Golick M, Pocoski J
Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA

PND55

USE OF TIME-TO-EVENT ANALYSES TO DEFINE EPISODES OF CARE IN SICKLE CELL DISEASE

 

Eworuke E, Kauf T
University of Florida, Gainesville, FL, USA

PND56

COMPARISON OF THE HEALTH CARE UTILIZATION AND COSTS OF MEDICALLY MANAGED PATIENTS VERSUS DEEP BRAIN STUMULATION PATIENTS WITH PARKINSON'S DISEASE

 

Wu CF1, Bockstedt L2, Halseth MJ2
1University of Minnesota, Minneapolis, MN, USA, 2Medtronic, Inc., Minneapolis, MN, USA

PND57

TEMPORAL TRENDS AND GEOGRAPHIC DISCREPANCIES IN PUBLIC EXPENDITURES WITH MULTIPLE SCLEROSIS DRUG TREATMENT IN BRAZIL

 

Takemoto MMS, Takemoto ML, Fernandes RA, Duarte GGF, Tolentino ACM, Santos PML, Moretti AIP
ANOVA - Knowledge Translation, Rio de Janeiro, Brazil

PND58

INPATIENT HEALTH RESOURCE UTILIZATION AMONG MULTIPLE SCLEROSIS PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM

 

Takemoto MMS, Takemoto ML, Fernandes RA, Tolentino ACM, Santos PML, Duarte GGF, Moretti AIP
ANOVA - Knowledge Translation, Rio de Janeiro, Brazil

PND59

MEDICATION TREATMENT PATTERNS FOR MULTIPLE SCLEROSIS PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM

 

Takemoto MMS, Takemoto ML, Fernandes RA, Duarte GGF, Moretti AIP, Santos PML, Tolentino ACM
ANOVA - Knowledge Translation, Rio de Janeiro, Brazil

Neurological Disorders – Research on Methods

PND60

TESTING A COMPUTERIZED METHOD OF ASSESSING MOVEMENT ACCURACY

 

Allen DD1, Ng M1, Greenwald CP2
1University of California, San Francisco/San Francisco State University, San Francisco, CA, USA, 2John Muir Hospital, Walnut Creek, CA, USA

PND61

EVALUATION OF CONSISTENCY BETWEEN MULTIPLE SCLEROSIS REGISTRY PUBLICATIONS

 

Lion M, Murphy D, Hettle R, Pietri G, Lock K, Moorcroft E
HERON Evidence Development Ltd, Luton, UK

PND62

MEDICATION POSSESSION RATIO (MPR): A COMPARISON OF TRADITIONAL MPR AND MODIFIED MPR FOR MULTIPLE SCLEROSIS (MS) PATIENTS PRESCRIBED DISEASE MODIFYING DRUGS (DMDS)

 

Dickson M1, Kozma C2, Phillips A3, Meletiche DM3
1University of South Carolina, Columbia, SC, USA, 2Independent Research Consultant/Adjunct Professor, University of South Carolina, St. Helena Island, SC, USA, 3EMD Serono, Inc., Rockland, MA, USA

PND63

WITHDRAWN

PND64

APPLICATION OF PREDICTIVE MODELING TO CLASSIFY FREQUENT SNORING IDENTIFIED FROM ROUTINE MEDICAL EXAMINATIONS USING THE NHANES DATABASE

 

Row B
University of Louisville, Louisville, KY, USA

PND65

TRANSLATABILITY ASSESSMENT OF THE POST-MIGRAINE QUESTIONNAIRE

 

Lambe J1, Acquadro C2, Conway K2, Ng-Mak D3, Healy C4, Norquist J4, Fitzgerald K5, Banderas B5, Evans C5, Kornstein A5
1MAPI Institute, Lyon, France, 2MAPI Research Trust, Lyon, France, 3Merck Sharp & Dohme Corp., West Point, PA, USA, 4Merck Research Laboratories, Merck Sharp & Dohme Corp, North Wales, PA, USA, 5MAPI Values, Boston, MA, USA



16th Annual International Meeting Main Page